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225 ABSTRACT
26 25B-NBOMe and 25C-NBOMe are potent 5-HT2A receptor agonists that have been associated with 
27 inducing hallucinogenic effects in drug users and severe intoxications. This paper describes the 
28 identification of their metabolites in rat and human urine by liquid chromatography (LC)-high 
29 resolution (HR)-MS/MS, the comparison of metabolite formation in vitro and in vivo and in different 
30 species, the general involvement of human cytochrome-P450 (CYP) isoenzymes on their metabolism 
31 steps, and their detectability by standard urine screening approaches (SUSAs) using GC-MS, LC-
32 MSn, or LC-HR-MS/MS. Both NBOMe derivatives were mainly metabolized by O-demethylation, 
33 O,O-bis-demethylation, hydroxylation, and combinations as well as by glucuronidation and sulfation 
34 of the main phase I metabolites. For 25B-NBOMe, 66 metabolites could be identified and 69 for 25C-
35 NBOMe. After application of low doses of both substances to rats, they were detectable mainly via 
36 their metabolites by both LC-based SUSAs. In case of acute intoxication, it was possible to detect 
37 25B-NBOMe and its metabolites in an authentic human urine sample when using the GC-MS SUSA 
38 in addition to the LC-based SUSAs. Initial CYP activity screening revealed the involvement of 
39 CYP1A2 and CYP3A4 in hydroxylation and CYP2C9 and CYP2C19 in O-demethylation. The 
40 presented study demonstrated that 25B-NBOMe and 25C-NBOMe were extensively metabolized and 
41 detectable by both LC-based SUSAs.
42
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352 1. Introduction
53
54 According to annual drug reports published by the European Monitoring Centre for Drugs and Drug 
55 Addiction (EMCDDA) and United Nations Office on Drugs and Crime (UNODC) [1-4], the 
56 availability and abuse of new psychoactive substances (NPS) increased during the last few years. 
57 Besides synthetic cannabinoids, cathinones, opioids, and tryptamines, the group of phenethylamines 
58 gained more importance in the last years [5]. Among others, the so-called 2C-type phenethylamines 
59 have been a constant feature in the detection of NPS [6]. They were first described by Alexander 
60 Shulgin in his book PIHKAL [7]. Like many phenethylamines, they have powerful psychoactive and 
61 stimulating effects [7,8]. Although many of them have been scheduled, new and uncontrolled 
62 alternatives have emerged. Structure-activity relationship studies revealed that derivatization of the 
63 primary amine of the 2C partial structure with a 2-methoxybenzyl substituent significantly increased 
64 the affinity toward the serotonin 5-HT2A receptor, thus, mediating potent hallucinogenic effects [9-
65 12]. The resulting 2C derivatives, the so-called NBOMes (N-2-methoxybenzyl phenethylamines), 
66 represent a new group of potent phenethylamine hallucinogens with high abuse potential. 2-(4-
67 Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxy¬phenyl)methyl]ethanamine (25B-NBOMe, 2C-B-
68 NBOMe), 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxy¬phenyl)methyl]ethanamine (25C-
69 NBOMe, 2C-C-NBOMe), and 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
70 methoxyphenyl)methyl]ethanamine, 25I-NBOMe, 2C-I-NBOMe) are among the most prevalent 
71 NBOMes. They are consumed depending on desired effects in reported dosages between 200-1,000 
72 µg, administered orally, sublingually, bucally or insufflated as powder or in solution as nose spray 
73 [8,13-20]. In recent years, NBOMe consumption was described in the context of acute and severe 
74 intoxications and fatalities [8,14-18,21,22]. In some cases, an unintentional intake of NBOMes, sold 
75 as LSD or 2Cs, were found to be responsible for adverse events [8,15,19,22]. However, 25B-NBOMe 
76 has also been employed in positron emission tomography (PET) in human volunteers to assess 
77 binding of this ligand in distinct brain areas and at non-psychoactive dosage levels [23,24].
478 Due to high receptor affinity and functional activity as full agonists, comparatively low doses, 
79 comparable to LSD, are needed to induce psychoactive effects. Consequently, the resulting low blood 
80 plasma or urine concentrations can make it challenging to identify and characterize the intake of 
81 NBOMes. In urine, the concentration of compounds is generally higher than in blood, but in many 
82 cases, metabolites rather than the parent compounds are the targets. Therefore, metabolism studies 
83 are needed for the development of urine screening approaches. The comprehensive metabolism study 
84 for 25I-NBOMe revealed that it was extensively metabolized and that the parent compound was 
85 found in urine only in small amounts [25].
86 Recently, Wohlfarth et al. [26] described the metabolism of 25C-NBOMe and 25I-NBOMe in mice 
87 and human urine as well as in human hepatocytes, and the reported results were consistent with 
88 previously published human and rat data for 25I-NBOMe [25]. For 25B-NBOMe, only limited data 
89 on its biotransformation are available [27,28], and for both compounds, no comprehensive data 
90 appear to be available on their detectability. Therefore, the aims of the present study were to 
91 investigate the metabolism of 25B-NBOMe and 25C-NBOMe in rats and humans with LC-HR-
92 MS/MS, to compare the results with in vitro and in vivo data and between different species, and to 
93 investigate their detectability by the authors’ standard urine screening approaches (SUSA) by GC-
94 MS, LC-MSn, and LC-HR-MS/MS, respectively.
95
96 2. Experimental
97
98 2.1. Chemicals and reagents
99
100 25B-NBOMe hydrochloride and 25C-NBOMe hydrochloride were purchased by LGC Standards 
101 (Wesel, Germany). Isolute HCX cartridges (130 mg, 3 mL) were obtained from Biotage (Uppsala, 
102 Sweden), isocitrate and isocitrate dehydrogenase from Sigma (Taufkirchen, Germany), NADP+ from 
103 Biomol (Hamburg, Germany), acetonitrile (LC-MS grade), ammonium formate (analytical grade), 
5104 formic acid (LC-MS grade), methanol (LC-MS grade), mixture (100,000 Fishman units/mL) of 
105 glucuronidase (EC No. 3.2.1.31) and arylsulfatase (EC No. 3.1.6.1) from Helix Pomatia, and all other 
106 chemicals and reagents (analytical grade) from VWR (Darmstadt, Germany). The baculovirus-
107 infected insect cell microsomes (Supersomes) containing 1 nmol/mL of human cDNA-expressed 
108 CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (2 nmol/mL), 
109 CYP3A4, or CYP3A5 (2 nmol/mL) were obtained from Corning (Amsterdam, The Netherlands). 
110 After delivery, the CYPs were thawed at 37°C, aliquoted, snap-frozen in liquid nitrogen, and stored at 
111 -80°C until use.
112
113 2.2. Urine samples
114
115 According to an established study design [29], the investigations were performed using rat urine 
116 samples from male Wistar rats (Charles River, Sulzfeld, Germany) for toxicological diagnostic 
117 reasons according to German law. Both compounds were administered in an aqueous suspension by 
118 gastric intubation of a single 10 mg/kg body weight (BW) dose for identification of the metabolites 
119 and of 0.1 mg/kg BW for screening (dose calculated based on common single dose reported in trip 
120 reports (https://www.erowid.org) and scaled by dose-by-factor approach from man to rat according to 
121 Sharma and McNeill [30]), respectively. The rats were housed in metabolism cages for 24 h, having 
122 water ad libitum. Urine was collected separately from feces over a 24 h period. Blank urine samples 
123 were collected before drug administration to verify that the samples were free of interfering 
124 compounds. The samples were directly analyzed and then stored at -20°C. 
125 In addition, for 25B-NBOMe, an authentic ante mortem human urine sample after unintentional 
126 intake of an unknown dose of 25B-NBOMe (declared as 2C-B) submitted to the authors’ laboratory 
127 for toxicological diagnostics was also analyzed.
128
129 2.3. Sample preparation
6130 2.3.1. Sample preparation for identification of phase I metabolites by LC-HR-MS/MS
131
132 According to a published procedure [29], 2 mL of urine was adjusted to pH 5.2 with acetic acid (1 M, 
133 approximately 50 μL) and incubated at 50 °C for 2 h with 50 μL of a mixture of glucuronidase and 
134 arylsulfatase. The urine sample was then loaded on an HCX cartridge previously conditioned with 1 
135 mL of methanol and 1 mL of water. After passage of the sample, the cartridge was washed with 1 mL 
136 of water, 1 mL of 0.01 M hydrochloric acid, and again with 1 mL of water. The acidic and neutral 
137 compounds were eluted with 1 mL of methanol into a 1.5 mL reaction vial and evaporated to dryness 
138 under a stream of nitrogen. In the same reaction vial, the basic compounds were eluted with 1 mL of 
139 a freshly prepared mixture of methanol/aqueous ammonia 32% (98:2, v/v). After another evaporation 
140 step the residues were reconstituted with 50 μL of a mixture of eluent A and B (1:1, v/v) for LC-HR-
141 MS/MS analysis. A 5-μL aliquot was then injected onto the LC-HR-MS/MS. 
142
143 2.3.2. Sample Preparation for the identification of phase I metabolites and MBPs
144
145 According to a published procedure [29], 100 μL of urine was mixed with 500 μL of acetonitrile for 
146 precipitation. After shaking and centrifugation, the supernatant was gently evaporated to dryness and 
147 reconstituted in 50 μL of a mixture of 10 mM aqueous ammonium formate buffer and acetonitrile 
148 (1:1, v/v) and 5 μL injected onto the LC-HR-MS/MS system.
149  
150 2.4. Incubations for initial CYP activity screening studies
151
152 According to standard procedures [29,31], microsomal incubations were performed at 37°C at a 
153 concentration of 25 μM 25B-NBOMe and 25C-NBOMe, respectively, with the CYP isoenzymes (75 
154 pmol/mL, each) CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
155 CYP3A4, or CYP3A5 for 30 min. Besides enzymes and substrates, the incubation mixtures (final 
7156 volume, 50 μL) contained 90 mM phosphate buffer (pH 7.4), 5 mM Mg2+, 5 mM isocitrate, 1.2 mM 
157 NADP+, 0.5 U/mL isocitrate dehydrogenase, and 200 U/mL superoxide dismutase. For incubations 
158 with CYP2A6 and CYP2C9, phosphate buffer was replaced with 45 mM or 90 mM Tris buffer, 
159 respectively, according to the Gentest manual. Reactions were initiated by addition of the CYP 
160 enzymes and stopped with 50 μL of ice-cold acetonitrile. The solution was centrifuged for 2 min at 
161 14,000 rpm; 70 μL of the supernatant phase were transferred to an autosampler vial and 5 µL injected 
162 onto the LC-HR-MS/MS system.
163
164 2.5. LC-HR-MS/MS instrumentation for identification of phase I and II metabolites and CYP initial 
165 screening
166
167 According to a published procedure [32], the extracts were analyzed using a ThermoFisher Scientific 
168 (TF, Dreieich, Germany) Dionex UltiMate 3000 RS pump consisting of a degasser, a quaternary 
169 pump, and an UltiMate autosampler, coupled to a TF Q-Exactive Plus system equipped with a heated 
170 electrospray ionization (HESI)-II source. The instrument was used in positive or in negative 
171 ionization mode. Mass calibration was performed prior to analysis according to the manufacturer’s 
172 recommendations using external mass calibration.
173 Gradient elution was run on a TF Accucore PhenylHexyl column (100 mm x 2.1 mm, 2.6 µm). The 
174 mobile phases consisted of 2 mM aqueous ammonium formate containing formic acid (0.1%, v/v) and 
175 acetonitrile (1%, v/v) (pH 3, eluent A) and 2 mM ammonium formate solution with 
176 acetonitrile:methanol (50:50, v/v) containing formic acid (0.1%, v/v) and water (1%, v/v) (eluent B). 
177 The gradient and flow rate were programmed as follows: 0-1 min hold 99% A, 1-16 min 95% A to 
178 5% A, 16-18 min hold 5% A, and 18-20 min hold 99% A, constantly at 500 μL/min.
179 The HESI-II source conditions were as follows: sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 
180 AU; spray voltage, 3.00 (positive polarity) and -4.00 kV (negative polarity); heater temperature, 
181 320°C; ion transfer capillary temperature, 320°C; and S-lens RF level, 60.0. Mass spectrometry was 
8182 performed in positive and negative polarity mode using full scan (FS) data and a subsequent data 
183 dependent acquisition (DDA) mode with an inclusion list on the masses of interest (phase I or phase 
184 II metabolites). Additionally, DDA runs without inclusion list (positive and negative mode) were 
185 performed to detect unexpected metabolites.
186 The settings for FS data acquisition were as follows: resolution, 35,000; microscans, 1; automatic 
187 gain control (AGC) target, 1e6; maximum injection time (IT), 120 ms; and scan range, m/z 100–700. 
188 The settings for the DDA mode with and without an inclusion list were as follows: resolution, 17,500; 
189 microscans 1, AGC target, 2e5; maximum IT, 250 ms; isolation window, 1.0 m/z, HCD with stepped 
190 normalized collision energy (NCE), 17.5, 35, and 52.5%; spectrum data type, profile; and underfill 
191 ratio, 0.5%. For the run without inclusion list, the five most intense precursor ions were transferred to 
192 an exclusion list for 1 s (dynamic exclusion).
193 For analyzing the initial CYP activity screening, the MS settings and the mobile phases as well as the 
194 gradient and flow rate were the same with the same inclusion list as for identification of phase I 
195 metabolites.
196
197 2.6. Standard urine screening procedures (SUSAs)
198
199 The SUSAs were performed as described in the following references: GC-MS SUSA [33,34], LC-
200 MSn SUSA [25,35], and LC-HR-MS/MS SUSA [25,36].
201
202 3. Results and discussion
203
204 3.1. Identification of metabolites
205 3.1.1. Identification of 25B-NBOMe and 25C-NBOMe and their phase I metabolites via HR-MS/MS 
206 fragmentation
207
9208 The HR-MS/MS fragmentation patterns and metabolite formation of 25B-NBOMe and 25C-
209 NBOMe were similar to those described for 25I-NBOMe [25]. Briefly, and for discussion purposes, 
210 the molecules were viewed as two distinct parts, i.e. the 4-halogenated 2,5-
211 dimethoxyphenethylamine (2C) part and the N-(2-methoxybenzyl) (NBOMe) part. Due to the high 
212 number of metabolites, the fragmentation patterns could not be discussed in detail for all metabolites 
213 and only the typical fragment ions used for identification will be discussed. 
214 In general, for both compounds and their metabolites, the precursor masses and the most abundant 
215 fragment ions formed from unmodified or modified NBOMe parts were used to identify the 
216 corresponding metabolites. As expected, the fragment ions formed by the NBOMe part were identical 
217 for 25B-NBOMe and 25C-NBOMe. To confirm the predicted chemical structure of the metabolites, 
218 the corresponding 2C fragment ions (Table S1 in the electronic supplementary data for 25B-NBOMe 
219 and Table S2 for 25C-NBOMe) were used. For the N-dealkylated metabolites, no fragment ions of 
220 the NBOMe part could be detected, but characteristic 2C fragmentation patterns for the bromo and 
221 chloro analogues (Tables S1 and S2). The precursor masses (PM) are given with the calculated exact 
222 masses.
223 25B-NBOMe (B1; PM at m/z 380.0856, M+H+) showed a fragmentation pattern characteristic also 
224 for most of the detected metabolites. The most abundant fragment ion of m/z 121.0653 represented 
225 the cleavage of the NBOMe moiety, followed by the loss of the methoxy group (-30.0105 u) 
226 producing the tropylium ion of m/z 91.0548. The fragment ions representing the 2C part showed low 
227 abundances of at least 1 % (Table S1). The fragment ion of m/z 258.0124 representing the 2C-B 
228 iminium ion resulted from benzyl cleavage. A loss of NH (- 15.0109 u) formed the fragment ion of 
229 m/z 243.0021 followed by a loss of a methyl radical (- 15.0235 u) of one of the two methoxy groups in 
230 the 2C part resulting in fragment ion of m/z 227.9786. For the MS2 spectrum of 25I-NBOMe, a 
231 rearrangement was described in the literature [25]. In the parent spectrum of 25B-NBOMe, one 
232 fragment ion could also be formed by the same rearrangement. The fragment ion of m/z 363.0596 
233 resulted from a loss of ammonia (-17.0263 u) and appeared consistent with the postulated 
10
234 rearrangement reaction. Few MS2 spectra of metabolites also showed possible rearranged fragment 
235 ions.
236 The fragmentation patterns of 25C-NBOMe (C1; PM at m/z 336.1361, M+H+) corresponded to those 
237 of 25B-NBOMe and 25I-NBOMe. Similarly, the most abundant fragment ions in MS2 were formed 
238 by cleavage of the NBOMe moiety producing fragment ions of m/z 91.0548 and 121.0653. Also, the 
239 fragment ions representing the 2C part showed a lower abundance of about 1 % (Table S2). The 
240 fragment ions of m/z 214.0629, m/z 199.0526, and m/z 184.0291 represented the 2C-C iminium ion, 
241 the subsequent loss of NH (- 15.0109 u), and the loss of a methyl radical (- 15.0235 u) of one of the 
242 two methoxy groups, respectively. In the spectrum of 25C-NBOMe, no fragment ions indicating the 
243 rearrangement were detected, possibly due to low relative abundance. However, in the MS2 spectra of 
244 some 25C-NBOMe metabolites (e.g. O-demethyl metabolite isomers 1 and 2, C16 and C17), some 
245 rearranged fragment ions could also be detected. Overall, 35 phase I metabolites could be detected for 
246 25B-NBOMe in urine and 36 for 25C-NBOMe, respectively. All phase I metabolites are listed in 
247 Tables S1 and S2 in the electronic supplementary data.
248 For metabolite identification based on the MS2 spectra, in most cases the representative fragment ion 
249 for the NBOMe part was used. Unmodified NBOMe parts led to a fragment ion of m/z 121.0653. The 
250 presence of this fragment ion led to the suggestion that the expected modification took place at the 2C 
251 part based on the predicted precursor mass for the metabolite. An unchanged fragment ion of m/z 
252 121.0653 could be seen for the parent compounds (B1 and C1) as well as for mono- and bis-
253 demethylated (B13, B14, B8 and C16, C17, C10), mono-hydroxylated (B29, B32 and C31, C32), bis-
254 hydroxylated (B35), combined mono-demethylated with mono-hydroxylated (B22), dehydrogenated 
255 (B20 and C24), dehydrogenated combined with mono-demethylated (B12 and C13), and mono-
256 hydroxylated (B27 and C30) metabolites. On the other hand, the fragment ion of m/z 137.0603 
257 represented mono-hydroxylation at the NBOMe part (B16, B23, B28, B30, B31 and C19, C25, C27, 
258 C33, C35). At the NBOMe moiety, bis-hydroxylation led to the fragment ion of m/z 153.0552 (B33, 
259 B34 and C34, C36) and O-demethylation to fragment ion of m/z 107.0497 (B7, B9, B10, B11, B15, 
11
260 B19, B21 and C8, C9, C11, C12, C14, C18, C21, C23, C26). The fragment ion of m/z 107.0497 
261 could also be found for the NBOMe mono-hydroxylated (B16, B23, B28, B31 and C19, C25, C27, 
262 C33) or NBOMe bis-hydroxylated (B34 and C34, C35, C36) metabolites, but consistently in 
263 combination with the fragment ions of m/z 137.0603 or m/z 153.0552 as mentioned above. Therefore, 
264 the absence of the fragment ions of m/z 137.0603 and 153.0552 indicated O-demethylation at the 
265 NBOMe part. O-Demethylation combined with mono-hydroxylation led to fragment ion of m/z 
266 123.0446 (B17, B18, B24, B25 and C20, C22, C28, C29). As mentioned above, all N-
267 demethoxybenzyl metabolites were identified based on the 2C part fragmentation patterns (B2–B6 
268 and C2–C7).
269 In summary, the fragmentation patterns of both NBOMes corresponded to those of 25I-NBOMe. 
270 Some compound-related characteristics were found for the bromo and chloro analogues as already 
271 described for 25I-NBOMe. All metabolites, which were O-demethylated at the NBOMe part (m/z 
272 107.0497), showed higher abundances for fragment ions representing the 2C part probably due to a 
273 hydrogen bond between the nitrogen and the hydroxy group resulting from O-demethylation at the 
274 NBOMe part [25]. In addition, for these metabolites, the corresponding 2C fragment ion carrying the 
275 nitrogen was represented by the 2C primary amine instead of the 2C iminium ion found for the parent 
276 compounds or metabolites, which were not O-demethylated at the NBOMe part.
277 It was not possible in this study to identify the demethylated position of the methoxy group (2’- or 5’-
278 position) or the position at which the NBOMe part was hydroxylated. Nevertheless, Wohlfarth et al. 
279 [26] synthesized six potential 25C-NBOMe metabolites (2’- and 5’-O-demethyl-25C-NBOMe and 3-
280 /4-/5- and 6-hydroxy-25C-NBOMe) to confirm the exact position of the metabolic reaction. They 
281 observed that both in vivo samples (mouse and human urine) showed prevalence for O-demethylation 
282 at the 5’-position. Furthermore, they observed that the most intense signal for a mono-hydroxylated 
283 metabolite was detected for 5-hydroxy-25C-NBOMe in human urine as well as in mouse urine. In 
284 general, Wohlfarth et al. described the same main metabolic steps compared to the present study and 
12
285 25I-NBOMe [25]. In accordance, Leth-Petersen et al. [28] described that the main metabolic step 
286 of 25B-NBOMe was also the 5’-O-demethylation in humans and pigs.
287
288 3.1.2. Identification of 25B-NBOMe and 25C-NBOMe and their phase I metabolites via HR-MS/MS 
289 fragmentation
290
291 The phase II metabolite formation and fragmentation patterns were very similar for both compounds 
292 and comparable with those described for 25I-NBOMe. For both compounds, the precursor masses 
293 and the most abundant fragment ions formed from unmodified or modified NBOMe part were used to 
294 identify the corresponding phase II metabolites. 2C fragment ions were used to confirm the predicted 
295 metabolites.
296 Overall, 31 phase II metabolites could be identified for 25B-NBOMe and 33 for 25C-NBOMe. A list 
297 of all phase II metabolites is given in Tables S3 and S4 in the electronic supplementary data. All 
298 glucuronides eliminated glucuronic acid (- 176.0321 u) and all sulfates sulfuric acid (- 79.9568 u). 
299 Thus, the rest of the spectra of phase II conjugates was in accordance with the spectrum of the 
300 corresponding phase I metabolite. Also, for some phase II metabolites, fragment ions formed by 
301 conjugated partial structures could be used to elucidate the position of the conjugation.
302 As already described for 2C derivatives [37] and 25I-NBOMe the metabolites formed after N-
303 demethoxybenzylation could further be conjugated by acetylation, glucuronidation, sulfation, or even 
304 combinations of them. Furthermore, in accordance to 25I-NBOMe, an O,O-bis-demethylation of the 
305 2C part led to a hydroquinone partial structure, which could further be conjugated with glutathione 
306 (GSH). The degradation products of GSH conjugated metabolites could be found for both 
307 compounds. Also the described conjugation catalyzed by catechol-O-methyl-transferase (COMT) 
308 could be found for both NBOMes forming O-methyl metabolites (B33ME and C24ME, C36ME), 
309 after bis-hydroxylation at the NBOMe part (m/z 167.0708) producing a catecholic partial structure.
310
13
311 3.2. Initial CYP activity screening
312
313 For identification of the CYPs catalyzing the initial metabolic steps, the ten most abundant human 
314 hepatic CYPs were incubated under conditions allowing a statement on the general involvement of a 
315 particular CYP enzyme. It should be kept in mind that these qualitative data did not reflect a 
316 quantitative contribution of a CYP to the hepatic clearance that would require the collection of 
317 enzyme kinetic data [38], which was beyond the scope of this study. As summarized in Tables 1 and 
318 2, CYP2C9 and CYP2C219 were involved in O-demethylation for both, 25B-NBOMe and 25C-
319 NBOMe, respectively, CYP1A2 and CYP3A4 in hydroxylation, and CYP3A4 in N-
320 demethoxybenzylation.
321
322 3.3. Proposed metabolic pathways
323
324 According to the 25B-NBOMe metabolites identified in human and rat urine after cleavage of 
325 conjugates and 25C-NBOMe metabolites identified in rat urine after cleavage of conjugates (Tables 
326 S1 and S2), the following metabolic pathways, depicted in Figs. 1 and 2, could be proposed.
327 As expected, both compounds underwent the same main metabolic steps. O-Demethylation led to the 
328 most abundant peaks in human and rat urine followed by O-bis-demethylation and /or by O-
329 demethylation plus hydroxylation. N-Demethoxybenzylation led to only small peaks in both species. 
330 However, the relative abundance of the different metabolites varied between the species, but it should 
331 also be kept in mind that the rat urines were pooled over 24 h and the human urine was collected at an 
332 unknown time after administration of an unknown dose. Finally, the relation of the metabolites may 
333 vary over the time of excretion. 
334 For both derivatives, the following phase I pathways could be found: mono-demethylation (B13–B15 
335 and C16–C18), bis-demethylation (B8–B10 and C10–C12), tris-demethylation (B7 and C8) of the 
336 methoxy groups, mono- and bis-hydroxylation (B29–B32, B34, B35, and C31–C33, C35, C36), N-
14
337 demethoxybenzylation (B6 and C5), and combinations of mono-hydroxylation with mono-
338 demethylation (B22–B25 and C26–C29), and bis-demethylation (B16–B19 and C19–C23) as well as 
339 bis-hydroxylation with mono-demethylation (B33 and C34), and N-demethoxybenzylation with 
340 mono-demethylation (B3, B4 and C2, C3) followed by oxidative deamination (B2) and oxidation to 
341 the corresponding carboxylic acid (B5 and C4). In addition, for 25C-NBOMe also N-
342 demethoxybenzylation with mono-hydroxylation (C7), and oxidation forming an amide structure 
343 (C6) could be predicted. Also, dehydro metabolites (B20 and C24) were found for both compounds. 
344 The presence of this metabolic step was already described for 25I-NBOMe [25].
345 Nielsen et al. [39] described dehydrogenation as a CYP-catalyzed reaction. The resulting double 
346 bond was located at the 2C moiety and not between the nitrogen and the α-carbon of the 2C moiety as 
347 confirmed with reference standard of the 25I-NBOMe imine. These compounds could further be 
348 metabolized by mono-demethylation (B11, B12 and C13–C15), bis-demethylation (C9), 
349 hydroxylation (B26–B28 and C30), and combination of mono-demethylation and hydroxylation 
350 (B21 and C25). However, the possibility could not be excluded that the dehydro compound could 
351 also be formed by artificial dehydration of the corresponding hydroxy metabolite. If hydroxylation 
352 took place at the α-position to the nitrogen forming an unstable hemiaminal, then this metabolite 
353 could further eliminate water under the ESI conditions described above. In summary, the metabolic 
354 pathways for 25B-NBOMe and 25C-NBOMe corresponded to those described for 25I-NBOMe, i.e. 
355 showing the same main phase I metabolism reactions.
356 The following phase II pathways could be proposed for humans and/or rats as given in Tables S3 and 
357 S4 and Figs. 1 and 2: sulfation (S) glucuronidation (G) and/or of the O-demethyl metabolites 
358 (B13/14S, B15S, B13G–B15G and C16/17S, C18S, C16G–C18G), of the O,O-bis-demethyl 
359 metabolites (B8S, B9/10S, B8G, B9/10G and C10S–C12S, C10G–C12G), of O,O,O-tris-demethyl 
360 metabolite (B7S, B7G and C8S, C8G), of the O-demethyl-hydroxy metabolites (B22S, B24/25S, 
361 B22G, B23, B24/25G and C22S, C27S, C28/29S), of the O,O-bis-demethyl-hydroxy metabolites 
362 (B16S, B17/18S, B16G, B19G and C20S, C19G–C22G), and of the hydroxy metabolites (B30G, 
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363 B31G and C31/32G, C33G). Glutathione (GSH) conjugation could be proposed for the O,O-bis-
364 demethyl metabolite isomer 1 (B8-GSH-1, B8-GSH-2 and C10-GSH-1, C10-GSH-2), N-acetylation 
365 (AC) for the N-demethoxybenzyl-O-demethyl metabolites (B3, B4 and C2, C3) followed by further 
366 sulfation and/or glucuronidation (B3AC+S, B4AC+S, B3/4AC+G and C3/4AC+S, C2/3AC+G), and 
367 O-methylation (ME) of the bis-hydroxy metabolite (C36ME) and the O-demethyl-bis-hydroxy 
368 metabolites (B33ME and C34ME). In summary, all phase II pathways could be proposed for both 
369 species except for glutathione conjugation, which was observed only in rats after administration of 
370 the high dose.
371
372 3.4. Comparison of metabolite formation in vitro and in vivo and in different species
373
374 In contrast to the development of new therapeutics drug, pharmacokinetic data are not routinely 
375 collected for NPS before emergence on the market. For ethical reasons, controlled human studies are 
376 not possible. Therefore, animal studies under controlled conditions are common in combination with 
377 human in vivo assays as described e.g. in refs. [25,26]. Both data can be confirmed by authentic 
378 human samples of e.g. intoxication cases. For development of urine screening approaches, it is 
379 important to know the possible target. Thus, any metabolites identified first in animal urine can 
380 become the main target in human urine considering e.g. inter-species and/or genetic variations in 
381 drug metabolism and transport. For this reason, Tables 3 and 4 list the phase I and II metabolites 
382 identified in this study compared to those detected in human liver microsomes (HLM) incubation, 
383 porcine liver microsomes (PLM) incubation, mouse urine (MU), authentic human urines (HU), or 
384 human hepatocyte (HP) incubation. Differences could be explained by species differences, higher 
385 doses, and/or different sampling time after administration.
386
387 3.4.1. 25B-NBOMe
388
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389 Boumrah et al. [27] described 21 phase I and II metabolites of 25B-NBOMe identified only in vitro 
390 after incubation with HLM and cofactors for CYPs and glucuronyl transferases. Leth-Petersen et al.  
391 [28]compared formation of phase I metabolites in HLM and PLM incubations. In the present study, 
392 35 phase I and 31 phase II metabolites have been identified in human and rat urine. According to 
393 Table 3, in both urine samples, various metabolites could be identified not described by Boumrah et 
394 al. or Leth-Petersen et al. Most of them were isomers of metabolites formed by combined metabolic 
395 reactions such as mono- and bis-O-demethylation with hydroxylation or O-demethylation with N-
396 dealkylation. Species differences occurred for the hydroxylation step because rats seemed to prefer 
397 hydroxylation at the 2C part whereas human biotransformation might result in preferential 
398 hydroxylation at the NBOMe part. Concerning phase II metabolism, Boumrah et al. investigated only 
399 the glucuronide formation. In the present study, sulfation, N-acetylation, and O-methylation were 
400 found in rat and human urine as further reactions. In addition, rats showed GSH conjugation and 
401 combinations of N-acetylation with sulfation or glucuronidation. In contrast, the N-glucuronide of the 
402 parent compound detected in HLM could not be found in the human or rat urine.
403
404 3.4.2. 25C-NBOMe
405
406 Table 4 summarizes the data obtained in rat urine and those in human hepatocytes and urines of 
407 humans and mice [26]. Concerning phase I metabolism, most metabolites were common for all 
408 species while the highest number was found in the rat urine probably due to the high dosage, urine 
409 collection time, sample preparations, and/or chromatographic separation. Some metabolites were 
410 only detected in rat urine such as the combined N-dealkylated and O-demethylated metabolites or 
411 various isomers of O,O-bis-demethyl-hydroxy metabolites. Wohlfarth et al. [26] described N-
412 oxidation and carbonylation in the hepatocyte incubation although it was not clear why this could not 
413 be found in their human and mice urine. As already described for 25B-NBOMe, rats seemed to 
414 preferentially hydroxylated at the 2C part and humans at the NBOMe part. Most phase II pathways 
17
415 could be proposed for all three species with the exception of O-acetylation, N-acetylation, GSH 
416 conjugation, and O-methylation. Again, the highest number of metabolites was identified in rat urine 
417 probably due to the reasons described above. 
418
419 3.5. Toxicological detection of 25B-NBOMe and 25C-NBOMe by SUSAs
420 3.5.1. GC-MS SUSA
421
422 Unfortunately, 25B-NBOMe and 25C-NBOMe and/or their metabolites could not be detected in rat 
423 urine after low dose administration (0.1 mg/kg BW). However, 25B-NBOMe and metabolites (Table 
424 5) could be detected in the human urine sample by GC-MS SUSA. The compound ingested by the 
425 user was believed to be 2C-B, which typically requires a ten-fold higher dose compared to 25B-
426 NBOMe [7]. Therefore, for acute and/or severe poisonings with NBOMes an intake could also be 
427 detected by GC-MS SUSA. 25C-NBOMe could only be detected after the high dose, enzymatic 
428 cleavage of conjugates, solid-phase extraction, and acetylation according to Welter et al. [31].
429
430 3.5.2. LC-MSn SUSA
431
432 The LC-MSn approach could detect 25B-NBOMe and 25C-NBOMe and/or their metabolites in rat 
433 urine after low dosage (0.1 mg/kg BW) as well as in the authentic human urine sample. A list of the 
434 detected metabolites is given in Table 6. As already mentioned above, the differences of detected 
435 analytes in the human and rat urine samples could be caused by different doses and urine collection 
436 times.
437
438 3.5.3. LC-HR-MS/MS SUSA
439
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440 As expected, this approach was also able to reveal 25B-NBOMe and 25C-NBOMe and/or their 
441 metabolites in rat urine after low dosage (0.1 mg/kg BW) as well as in the authentic human urine 
442 sample. A list of the detected metabolites is given in Table 7. Again, the differences of detected 
443 analytes in the human and rat urine samples could be caused by different doses and urine collection 
444 times. Mostly due to the lethal overdose, the parent compound gave one of the most abundant signals 
445 in the human urine sample. However, low dose rat urine studies showed that the parent compound 
446 should not be expected in high amounts after recreational use. Therefore, it should not be used as the 
447 only target for NBOMe urine screening.
448
449 4. Conclusions
450
451 Both, 25B-NBOMe and 25C-NBOMe were extensively metabolized similar to 25I-NBOMe 
452 including O-demethylation, O,O-bis-demethylation, and hydroxylations as predominant pathways in 
453 humans and rats. This was in accordance to published human and animal in vitro and in vivo data. 
454 Several CYP isoenzymes were involved in formation of the main metabolites. An intake could be 
455 detected mainly via their metabolites by low and high resolution LC-MS SUSAs and by GC-MS 
456 SUSA only in overdose cases.
457
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Table 1 General involvement of the CYP isoenzymes on the formation of the given 25B-NBOMe 
metabolites, numbering according to Table S1 
Metabolite CYP
1A2
CYP
2A6
CYP
2B6
CYP
2C8
CYP
2C9
CYP
2C19
CYP
2D6
CYP
2E1
CYP
3A4
CYP
3A5
N-Demethoxybenzyl (B6) + + + +
O-Demethyl isomer 1 (B13) + + + +
O-Demethyl isomer 2 (B14) + + + + +
O-Demethyl isomer 3 (B15) + + + + + +
Dehydro- (B20) + + +
Hydroxy isomer 2 (B30) + + + +
Hydroxy isomer 3 (B31) + + + +
Hydroxy isomer 4 (B32) + +
Table 2 General involvement of the CYP isoenzymes on the formation of the given 25C-NBOMe 
metabolites, numbering according to Table S2
Metabolite CYP
1A2
CYP
2A6
CYP
2B6
CYP
2C8
CYP
2C9
CYP
2C19
CYP
2D6
CYP
2E1
CYP
3A4
CYP
3A5
N-Demethoxybenzyl (C5) + + + +
O-Demethyl isomer 1 (C16) + + + +
O-Demethyl isomer 2 (C17) + + + + +
O-Demethyl isomer 3 (C18) + + + + + +
Dehydro- (C24) + + +
Hydroxy isomer 3 (C33) + + + +
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Table 3  25B-NBOMe phase I and II metabolites detected in rat (RU) and human (HU) urine 
compared to those detected in human liver microsome (HLM) incubation published by Boumrah et 
al. [27] and in HLM and porcine liver microsome (PLM) incubations published by Leth-Petersen et 
al. [28]. Numbering according to Tables S1 and S3, * = metabolite only described in references 
[27,28]
No. Metabolite RU HU HLM
 [27]
HLM
 [28]
PLM
 [28]
B1 25B-NBOMe + + + + +
B2 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-deamino-hydroxy-) + +
B3 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 1 + +
B4 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 2 + +
B5 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-deamino-carboxy-) + +
B6 25B-NBOMe-M (N-demethoxybenzyl-) + + + + +
B7 25B-NBOMe-M (O,O,O-tris-demethyl-) + +
B8 25B-NBOMe-M (O,O-bis-demethyl-) isomer 1 + + + + +
B9 25B-NBOMe-M (O,O-bis-demethyl-) isomer 2 + + + +
B10 25B-NBOMe-M (O,O-bis-demethyl-) isomer 3 + + + + +
B11 25B-NBOMe-M (O-demethyl-dehydro-) isomer 1 + +
B12 25B-NBOMe-M (O-demethyl-dehydro-) isomer 2 +
B13 25B-NBOMe-M (O-demethyl-) isomer 1 + + + + +
B14 25B-NBOMe-M (O-demethyl-) isomer 2 + + + + +
B15 25B-NBOMe-M (O-demethyl-) isomer 3 + + + + +
B16 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 1 +
B17 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 2 + +
B18 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 3 + +
B19 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 4 +
B20 25B-NBOMe-M (dehydro-) + + +
B21 25B-NBOMe-M (O-demethyl-dehydro-hydroxy-) +
B22 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 1 + +
B23 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 2 + + + +
B24 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 3 + + + +
B25 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 4 + + + +
B26 25B-NBOMe-M (dehydro-hydroxy-) isomer 1 +
B27 25B-NBOMe-M (dehydro-hydroxy-) isomer 2 +
B28 25B-NBOMe-M (dehydro-hydroxy-) isomer 3 + +
B29 25B-NBOMe-M (hydroxy-) isomer 1 +
B30 25B-NBOMe-M (hydroxy-) isomer 2 + + + +
B31 25B-NBOMe-M (hydroxy-) isomer 3 + + +
B32 25B-NBOMe-M (hydroxy-) isomer 4 + + +
B33 25B-NBOMe-M (O-demethyl-bis-hydroxy-) +
B34 25B-NBOMe-M (bis-hydroxy-) isomer 1 +
B35 25B-NBOMe-M (bis-hydroxy-) isomer 2 + +
M11 25B-NBOMe-M (carbonyl) * +
B3
AC
25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 1 + +
B4
AC
25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 2 + +
27
B3
AC+S
25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl sulfate isomer 1 +
B4
AC+S
25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl sulfate isomer 2 +
B8
GSH-1
25B-NBOMe-M
(O,O-bis-demethyl-) S-methyl +
B33
ME
25B-NBOMe-M
(O-demethyl-bis-hydroxy-) O-methyl + +
B7
S
25B-NBOMe-M
(O,O,O-tris-demethyl-) sulfate +
B3/4
G
25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) glucuronide +
B8
S
25B-NBOMe-M
(O,O-bis-demethyl-) sulfate isomer 1 + +
B9/10
S
25B-NBOMe-M
(O,O-bis-demethyl-) sulfate isomer 2 +
B13/14
S
25B-NBOMe-M
(O-demethyl-) sulfate isomer 1 + +
B15
S
25B-NBOMe-M
(O-demethyl-) sulfate isomer 2 +
B16
S
25B-NBOMe-M
(O,O-bis-demethyl-hydroxy-) sulfate isomer 1 +
B17/18
S
25B-NBOMe-M
(O,O-bis-demethyl-hydroxy-) sulfate isomer 2 +
B22
S
25B-NBOMe-M 
(O-demethyl-hydroxy-) sulfate isomer 1 +
B24/25
S
25B-NBOMe-M 
(O-demethyl-hydroxy-) sulfate isomer 2 + +
B3/4
AC+G
25B-NBOMe-M 
(N-demethoxybenzyl-O-demethyl-) N-acetyl glucuronide +
B8
GSH-2
25B-NBOMe-M 
(O,O-bis-demethyl-) acetylcysteine +
B7
G
25B-NBOMe-M 
(O,O,O-tris-demethyl-) glucuronide +
B8
G
25B-NBOMe-M 
(O,O-bis-demethyl-) glucuronide isomer 1 + + +
B9/10
G
25B-NBOMe-M 
(O,O-bis-demethyl-) glucuronide isomer 2 + + +
B13
G
25B-NBOMe-M 
(O-demethyl-) glucuronide isomer 1 + + +
B14
G
25B-NBOMe-M 
(O-demethyl-) glucuronide isomer 2 + + +
B15
G
25B-NBOMe-M 
(O-demethyl-) glucuronide isomer 3 + + +
B16
G
25B-NBOMe-M 
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 1 +
B19
G
25B-NBOMe-M 
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 2 +
B23
G
25B-NBOMe-M 
(O-demethyl-hydroxy-) glucuronide isomer 1 + +
B22
G
25B-NBOMe-M 
(O-demethyl-hydroxy-) glucuronide isomer 2 +
B24/25
G
25B-NBOMe-M 
(O-demethyl-hydroxy-) glucuronide isomer 3 + +
B30
G
25B-NBOMe-M 
(hydroxy-) glucuronide isomer 1 + +
B31
G
25B-NBOMe-M 
(hydroxy-) glucuronide isomer 2 + +
M21 25B-NBOMe-M
N-glucuronide * +
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Table 4  25C-NBOMe phase I and II metabolites detected in rat (RU) urine compared to those in 
authentic human urines (HU), mouse urine (MU) and human hepatocyte (HP) incubation as 
published by Wohlfarth et al. [26]. Numbering according to Tables S2 and S4, * = metabolite only 
described in reference [26]
No. Metabolite RU HU
 [26]
MU
 [26]
HP
 [26]
C1 25C-NBOMe + + + +
C2 25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 1 +
C3 25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 2 +
C4 25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-deamino-carboxy-) +
C5 25C-NBOMe-M (N-demethoxybenzyl-) + + +
C6 25C-NBOMe-M (N-demethoxybenzyl-oxo-) +
C7 25C-NBOMe-M (N-demethoxybenzyl-hydroxy-) +
C8 25C-NBOMe-M (O,O,O-tris-demethyl-) +
C9 25C-NBOMe-M (O,O-bis-demethyl-dehydro-) +
C10 25C-NBOMe-M (O,O-bis-demethyl-) isomer 1 + +
C11 25C-NBOMe-M (O,O-bis-demethyl-) isomer 2 + + +
C12 25C-NBOMe-M (O,O-bis-demethyl-) isomer 3 + + +
C13 25C-NBOMe-M (O-demethyl-dehydro-) isomer 1 +
C14 25C-NBOMe-M (O-demethyl-dehydro-) isomer 2 +
C15 25C-NBOMe-M (O-demethyl-dehydro-) isomer 3 +
C16 25C-NBOMe-M (O-demethyl-) isomer 1 + + + +
C17 25C-NBOMe-M (O-demethyl-) isomer 2 + + + +
C18 25C-NBOMe-M (O-demethyl-) isomer 3 + + +
C19 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 1 +
C20 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 2 + +
C21 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 3 +
C22 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 4 +
C23 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 5 +
C24 25C-NBOMe-M (dehydro-) +
C25 25C-NBOMe-M (O-demethyl-dehydro-hydroxy-) +
C26 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 1 +
C27 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 2 + + +
C28 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 3 + + + +
C29 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 4 +
C30 25C-NBOMe-M (dehydro-hydroxy-) +
C31 25C-NBOMe-M (hydroxy-) isomer 1 +
C32 25C-NBOMe-M (hydroxy-) isomer 2 +
C33 25C-NBOMe-M (hydroxy-) isomer 3 + + + +
C34 25C-NBOMe-M (O-demethyl-bis-hydroxy-) + +
C35 25C-NBOMe-M (bis-hydroxy-) isomer 1 +
C36 25C-NBOMe-M (bis-hydroxy-) isomer 2 +
C-Hp-21 25C-NBOMe-M (N-oxide) * +
C-Hp-22 25C-NBOMe-M (carbonyl) * +
C2
AC
25C-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 1 +
C3
AC
25C-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 2 +
C7
AC
25C-NBOMe-M
(N-demethoxybenzyl-O-demethyl-hydroxy-) N-acetyl +
C3/4
AC+S
25C-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl sulfate +
C10
GSH-1
25C-NBOMe-M
(O,O-bis-demethyl-) S-methyl +
C34 25C-NBOMe-M +
29
ME (O-demethyl-bis-hydroxy-) O-methyl
C8
S
25C-NBOMe-M
(O,O,O-tris-demethyl-) sulfate +
C2/3
G
25C-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) glucuronide +
C36
ME
25C-NBOMe-M
(bis-hydroxy-) O-methyl +
C10
S
25C-NBOMe-M
(O,O-bis-demethyl-) sulfate isomer 1 +
C11
S
25C-NBOMe-M
(O,O-bis-demethyl-) sulfate isomer 2 +
C12
S
25C-NBOMe-M
(O,O-bis-demethyl-) sulfate isomer 3 + + +
C16/17
S
25C-NBOMe-M
(O-demethyl-) sulfate isomer 1 + + + +
C18
S
25C-NBOMe-M
(O-demethyl-) sulfate isomer 2 + +
C20
S
25C-NBOMe-M
(O,O-bis-demethyl-hydroxy-) sulfate +
C22
S
25C-NBOMe-M
(O-demethyl-hydroxy-) sulfate +
C2/3
AC+G
25C-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl glucuronide +
C10
GSH-2
25C-NBOMe-M
(O,O-bis-demethyl-) acetylcysteine +
C8
G
25C-NBOMe-M
(O,O,O-tris-demethyl-) glucuronide + +
C10
G
25C-NBOMe-M
(O,O-bis-demethyl-) glucuronide isomer 1 + + +
C11
G
25C-NBOMe-M
(O,O-bis-demethyl-) glucuronide isomer 2 + + +
C12
G
25C-NBOMe-M
(O,O-bis-demethyl-) glucuronide isomer 3 + +
C16
G
25C-NBOMe-M
(O-demethyl-) glucuronide isomer 1 + + + +
C17
G
25C-NBOMe-M
(O-demethyl-) glucuronide isomer 2 + +
C18
G
25C-NBOMe-M
(O-demethyl-) glucuronide isomer 3 + +
C19
G
25C-NBOMe-M
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 1 +
C20
G
25C-NBOMe-M
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 2 +
C21
G
25C-NBOMe-M
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 3 +
C22
G
25C-NBOMe-M
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 4 +
C27
G
25C-NBOMe-M
(O-demethyl-hydroxy-) glucuronide isomer 1 +
C28/29
G
25C-NBOMe-M
(O-demethyl-hydroxy-) glucuronide isomer 2 + +
C31/32
G
25C-NBOMe-M
(hydroxy-) glucuronide isomer 1 +
C33
G
25C-NBOMe-M
(hydroxy-) glucuronide isomer 2 + + + +
C-Hp-6 25C-NBOMe-M
(O-demethyl-hydroxy-) glucuronide isomer * +
C-Hp-8 25C-NBOMe-M
(hydroxy-) glucuronide isomer * +
C-Hp-10 25C-NBOMe-M
(O-demethyl-hydroxy-) glucuronide isomer * +
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C-Hp-18 25C-NBOMe-M
(hydroxy-) sulfate * +
C-Hp-19 25C-NBOMe-M
(hydroxy-) sulfate * +
C-MH-21 25C-NBOMe-M
(O-demethyl-) O-acetyl * +
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Table 5 25B-NBOMe and its metabolites, molecular mass, five most abundant EI-GC-MS 
fragment ions, retention indices (RI), and detectability in rat urine (RU) or human urine (HU) by GC-
MS SUSA. The numbers correspond to those of Table S1.
No. Target for SUSA Molecular 
mass, u
GC-MS fragment ions, m/z and their relative 
intensities, %
RI Detected in 
urine 
sample
B1 25B-NBOMe AC 421 121 (100), 150 (9), 229 (12), 242 (33), 421 (2) 2920 HU
B2 25B-NBOMe-M
(N-demethoxybenzyl-deamino-O-demethyl-
hydroxy-) 2AC
330 215 (55), 228 (100), 246 (10), 288 (15), 330 (4) 2160 HU
B3/B4 25B-NBOMe-M 
(N-demethoxybenzyl -O-demethyl-) isomer 1 / 
isomer 2 2AC
329 215 (17), 228 (100), 270 (10), 287 (21), 329 (8) 2440 HU
B6 25B-NBOMe-M 
(N-demethoxybenzyl -) AC
301 148 (39), 199 (12), 229 (31), 242 (100), 301 (15) 2180 HU
B9/10 25B-NBOMe-M
(O,O-bis-demethyl-) isomer 2 / isomer 3 3AC
477 107 (78), 178 (100), 228 (42), 270 (12), 477 (1) 3020 HU
B13/14 25B-NBOMe-M 
(O-demethyl-) isomer 1 / isomer 2 2AC
449 121 (100), 192 (22), 228 (19), 270 (3), 449 (2) 3000 HU
32
Table 6 25B-NBOMe, 25C-NBOMe, and their metabolites, protonated precursor ions, 
characteristic MS2 and MS3 fragment ions, retention time (RT), and detectability in rat urine (RU) or 
human urine (HU, 25B-NBOMe) by LC-MSn SUSA. The numbers correspond to those of Tables S1-
S4.
No. Target for SUSA Precursor 
ions, m/z
MS2 fragment ions, m/z and 
relative intensity, %
MS3 fragment ions, m/z and 
relative intensity, % on the ion 
given in bold
RT, 
min
Detected 
in urine 
sample
B1 25B-NBOMe 380 121 (100), 179 (10), 243 (10), 255 
(18), 258 (14), 269 (10), 284 (15)
121: 91 (30), 93 (100)
255: 148 (10), 176 (100), 225 
(44)
14.6 HU
B9 25B-NBOMe-M
(O,O-bis-demethyl-) isomer 2
352 107 (1), 229 (56), 246 (100) 229: 135 (5), 150 (100)
246: 135 (3), 150 (51), 214 (100)
9.7 HU
B13 25B-NBOMe-M 
(O-demethyl-) isomer 1
366 121 (100), 229 (3), 241 (7), 244 (12), 
270 (26)
121: 91 (24), 93 (100)
270: 145 (6), 224 (7), 239 (100)
11.5 HU
B14 25B-NBOMe-M 
(O-demethyl-) isomer 2
366 121 (88), 241 (100), 257 (92), 258 
(37), 270 (51)
241: 147 (5), 162 (100)
257: 149 (46), 162 (55), 225 
(100)
12.3 HU, RU
B8
G
25B-NBOMe-M
(O,O-bis-demethyl-) 
glucuronide isomer 1
528 227 (8), 244 (4), 335 (7), 352 (100) 352: 121 (100), 227 (55), 244 
(18), 256 (21), 273 (7)
5.9 RU
B14
G
25B-NBOMe-M 
(O-demethyl-) 
glucuronide isomer 2
542 244 (2), 270 (2), 349 (3), 366 (100) 349: 241 (41), 255 (22), 270 
(100)
366: 121 (100), 241 (4), 244 (6), 
270 (17)
9.4 HU, RU
C16 25C-NBOMe-M 
(O-demethyl-) isomer 1
322 91 (9), 121 (100), 197 (9), 200 (11), 
214 (5)
121: 91 (22), 93 (100) 13.1 RU
C10
G
25C-NBOMe-M
(O,O-bis-demethyl-) 
glucuronide isomer 1
484 183 (15), 200 (4), 291 (11), 308 (100) 291: 121 (47), 183 (100), 255 
(23)
308: 121 (100), 183 (51), 200 
(21)
6.4 RU
C11
G
25C-NBOMe-M
(O,O-bis-demethyl-) 
glucuronide isomer 2
484 185 (38), 202 (47), 308 (100), 378 
(20)
202: 150 (21), 157 (10), 170 
(100)
308: 185 (84), 202 (100)
8.2 RU
C17
G
25C-NBOMe-M 
(O-demethyl-) 
glucuronide isomer 2
498 185 (1), 200 (2), 305 (2), 322 (100) 322: 121 (100), 197 (11), 200 
(10), 214 (5)
9.9 RU
C28/29
G
25C-NBOMe-M 
(O-demethyl-hydroxy-) 
glucuronide isomer 2
514 216 (2), 321 (5), 338 (100) 338: 121 (100), 198 (5), 216 (3), 
230 (1), 303 (7)
8.6 RU
33
Table 7 25B-NBOMe, 25C-NBOMe, and their metabolites, calculated masses of their precursor 
ions, retention times (RT) recorded in rat urine or human urine (25B-NBOMe, 25C-NBOMe not 
tested, n.t.) by LC-HR-MS/MS SUSA. The numbers correspond to those of Tables S1-S4 (D = 
detection of the precursor ion in MS1, I = identification via MS1 and MS2).
No. Targets in SUSA Calculated exact 
masses of 
precursor ions, 
m/z
RT, min Human 
urine
Rat urine
0.1 mg/kg 
BW
B1 25B-NBOMe 380.0856 6.0 I
B5 25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-deamino-carboxy-)
258.9606 5.3 D D
B8 25B-NBOMe-M
(O,O-bis-demethyl-) isomer 1
352.0543 5.0 I D
B9 25B-NBOMe-M
(O,O-bis-demethyl-) isomer 2
352.0543 5.3 I D
B13 25B-NBOMe-M
(O-demethyl-) isomer 1
366.0699 5.3 I
B14 25B-NBOMe-M
(O-demethyl-) isomer 2
366.0699 5.8 I I
B30 25B-NBOMe-M
(hydroxy-) isomer 2
396.0805 5.4 D
B31 25B-NBOMe-M
(hydroxy-) isomer 3
396.0805 5.9 D
B3
AC
25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 1 
288.0230 5.4 D
B4
AC
25B-NBOMe-M
(N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 2
288.0230 5.5 D
B8
S
25B-NBOMe-M
(O,O-bis-demethyl-) sulfate isomer 1
432.0111 4.9 D D
B9/10
S
25B-NBOMe-M
(O,O-bis-demethyl-) sulfate isomer 2
432.0111 5.7 I
B13/14
S
25B-NBOMe-M
(O-demethyl-) sulfate isomer 1
446.0267 5.8 I
B24/25
S
25B-NBOMe-M
(O-demethyl-hydroxy-) sulfate isomer 2
462.0217 5.5 D
B7
G
25B-NBOMe-M
(O,O,O-tris-demethyl-) glucuronide 
514.0707 3.8 D
B8
G
25B-NBOMe-M
(O,O-bis-demethyl-) glucuronide isomer 1
528.0864 4.2 I I
B9/10
G
25B-NBOMe-M
(O,O-bis-demethyl-) glucuronide isomer 2
528.0864 4.8 D D
B13
G
25B-NBOMe-M
(O-demethyl-) glucuronide isomer 1
542.1020 4.6 I
B14
G
25B-NBOMe-M
(O-demethyl-) glucuronide isomer 2
542.1020 5.2 I I
B19
G
25B-NBOMe-M
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 2
544.0813 4.5 D
B23
G
25B-NBOMe-M
(O-demethyl-hydroxy-) glucuronide isomer 1
558.0969 4.7 D
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B22
G
25B-NBOMe-M
(O-demethyl-hydroxy-) glucuronide isomer 2
558.0969 4.8 D
C11 25C-NBOMe-M
(O,O-bis-demethyl-) isomer 2
308.1048 4.6 n.t. D
C12 25C-NBOMe-M
(O,O-bis-demethyl-) isomer 3
308.1048 4.8 n.t. D
C17 25C-NBOMe-M
(O-demethyl-) isomer 2
322.1204 5.1 n.t. D
C8
G
25C-NBOMe-M
(O,O,O-tris-demethyl-) glucuronide
470.1212 3.5 n.t. I
C10
G
25C-NBOMe-M
(O,O-bis-demethyl-) glucuronide isomer 1
484.1369 3.8 n.t. I
C11
G
25C-NBOMe-M
(O,O-bis-demethyl-) glucuronide isomer 2
484.1369 4.4 n.t. I
C16
G
25C-NBOMe-M
(O-demethyl-) glucuronide isomer 1
498.1525 4.3 n.t. D
C17
G
25C-NBOMe-M
(O-demethyl-) glucuronide isomer 2
498.1525 4.8 n.t. I
C18
G
25C-NBOMe-M
(O-demethyl-) glucuronide isomer 3
498.1525 5.2 n.t. D
C21
G
25B-NBOMe-M
(O,O-bis-demethyl-hydroxy-) glucuronide isomer 3
500.1318 4.1 n.t. D
C28/29
G
25B-NBOMe-M
(O-demethyl-hydroxy-) glucuronide isomer 2
514.1475 4.5 n.t. I
C31/32
G
25B-NBOMe-M
(hydroxy-) glucuronide isomer 1
528.1631 4.1 n.t. D
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Legends to Figures
Fig. 1 Metabolic pathways of 25B-NBOMe studied in rat (R) or human (H) urine as well as in 
incubations with human (L) or porcine (P) liver microsomes. Phase II metabolites: glucuronides (G), 
sulfates (S), glutathione conjugates (GSH), acetyl conjugates (AC), O-methyl conjugates (ME), 
acetyl conjugates combined with glucuronidation (AC+G), acetyl conjugates combined with 
sulfation (AC+S). Undefined position of O-demethylation or hydroxylation indicated by tildes. 
Numbering according to Tables S1 and S3.
Fig. 2 Metabolic pathways of 25C-NBOMe studied in rat (R), mouse (M), or human (H) urine as well 
as in incubations with human hepatocytes (C). Phase II metabolites: glucuronides (G), sulfates (S), 
glutathione conjugates (GSH), acetyl conjugates (AC), O-methyl conjugates (ME), acetyl conjugates 
combined with glucuronidation (AC+G), acetyl conjugates combined with sulfation (AC+S). 
Undefined position of O-demethylation or hydroxylation indicated by tildes. Numbering according to 
Tables S2 and S4.
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211 Table S1 List of 25B-NBOMe and its phase I metabolites together with the precursor mass (PM) 
12 recorded in MS1, the corresponding characteristic fragment ions (FI) in MS2, the calculated exact 
13 masses, the corresponding elemental composition, the deviation of the measured from the calculated 
14 masses, given as errors in parts per million (ppm), and the retention times (RT) in minutes (min). The 
15 metabolites were sorted by mass and RT.
No. Metabolite and characteristic ions
Measured accurate mass, m/z
Relative intensity 
in MS2, %
Calculated exact mass, 
m/z
Elemental 
composition
Error, 
ppm
RT, min
B1 25B-NBOMe 8.8
MS1 PM at m/z 380.0859 (M+H) 7 380.0856 C18H23O3NBr 0.84
MS2 FI at m/z 91.0549
FI at m/z 121.0651
FI at m/z 227.9777
FI at m/z 243.0010
FI at m/z 258.0126
FI at m/z 363.0597
58
100
1
1
0.2
0.3
91.0548
121.0653
227.9786
243.0021
258.0124
363.0596
C7H7
C8H9O
C9H9O2Br
C10H12O2Br
C10H13O2NBr
C18H20O3Br
1.37
-1.98
-3.91
-4.39
0.71
0.33
B2 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-deamino-hydroxy-) 6.5
MS1 PM at m/z 244.9820 (M-H) 5 244.9820 C9H10O3Br 2.73
MS2 FI at m/z 78.9176
FI at m/z 199.9474
FI at m/z 211.9476
FI at m/z 229.9584
100
9
12
76
78.9183
199.9473
211.9473
229.9584
Br
C7H5O2Br
C8H5O2Br
C8H7O3Br
-9.33
0.55
1.46
2.37
B3 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 1 3.9
MS1 PM at m/z 246.0123 (M+H) 1 246.0124 C9H13O2NBr -0.47
MS2 FI at m/z 135.0442
FI at m/z 150.0677
FI at m/z 213.9626
FI at m/z 228.9861
24
47
82
100
135.0446
150.0681
213.9629
228.9864
C8H7O2
C9H10O2
C8H7O2Br
C9H10O2Br
-3.00
-2.53
-1.59
-1.38
B4 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 2 4.0
MS1 PM at m/z 246.0130 (M+H) 3 246.0124 C9H13O2NBr 2.37
MS2 FI at m/z 135.0442
FI at m/z 150.0676
FI at m/z 213.9625
FI at m/z 228.9861
22
40
90
100
135.0446
150.0681
213.9629
228.9864
C8H7O2
C9H10O2
C8H7O2Br
C9H10O2Br
-3.00
-3.20
-2.06
-1.38
B5 25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-deamino-carboxy-) 6.3
MS1 PM at m/z 258.9610 (M-H) 1 258.9606 C9H8O4Br 1.56
MS2 FI at m/z 78.9176
FI at m/z 199.9473
FI at m/z 214.9709
100
81
5
78.9183
199.9473
214.9708
Br
C7H5O2Br
C8H8O2Br
-9.33
0
0.62
B6 25B-NBOMe-M (N-demethoxybenzyl-) 5.6
MS1 PM at m/z 260.0273 (M+H) 1 260.0281 C10H15O2NBr -2.95
MS2 FI at m/z 164.0830
FI at m/z 212.9543
FI at m/z 227.9776
FI at m/z 243.0013
22
39
100
90
164.0837
212.9551
227.9786
243.0021
C10H12O2
C8H6O2Br
C9H9O2Br
C10H12O2Br
-4.45
-3.83
-4.35
-3.15
B7 25B-NBOMe-M (O,O,O-tris-demethyl-) 5.1
MS1 PM at m/z 338.0392 (M+H) 9 338.0386 C15H17O3NBr 1.68
MS2 FI at m/z 107.0496
FI at m/z 136.0520
FI at m/z 214.9703
FI at m/z 231.9968
100
33
81
32
107.0497
136.0524
214.9708
231.9968
C7H7O
C8H8O2
C8H8O2Br
C8H11O2NBr
-0.84
-3.16
-2.17
0
B8 25B-NBOMe-M (O,O-bis-demethyl-) isomer 1 6.0
3MS1 PM at m/z 352.0542 (M+H) 5 352.0543 C16H19O3NBr -0.23
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 226.9700
FI at m/z 335.0267
57
100
1
0.5
91.0548
121.0653
226.9708
335.0283
C7H7
C8H9O
C9H8O2Br 
C16H16O3Br 
0
-2.81
-3.37
-4.72
B9 25B-NBOMe-M (O,O-bis-demethyl-) isomer 2 6.8
MS1 PM at m/z 352.0540 (M+H) 11 352.0543 C16H19O3NBr -0.80
MS2 FI at m/z 107.0495
FI at m/z 213.9630
FI at m/z 228.9858
FI at m/z 246.0124
100
31
90
29
107.0497
213.9629
228.9864
246.0124
C7H7O
C8H7O2Br
C9H10O2Br
C9H13O2NBr
-1.77
0.28
-2.69
0
B10 25B-NBOMe-M (O,O-bis-demethyl-) isomer 3 6.9
MS1 PM at m/z 352.0541 (M+H) 12 352.0543 C16H19O3NBr -0.52
MS2 FI at m/z 107.0495
FI at m/z 213.9623
FI at m/z 228.9858
FI at m/z 246.0124
100
32
89
29
107.0497
213.9629
228.9864
246.0124
C7H7O
C8H7O2Br
C9H10O2Br
C9H13O2NBr
-1.77
-3.00
-2.69
0
B11 25B-NBOMe-M (O-demethyl-dehydro-) isomer 1 6.7
MS1 PM at m/z 364.0540 (M+H) 25 364.0543 C17H19O3NBr -0.77
MS2 FI at m/z 107.0495
FI at m/z 228.9857
FI at m/z 258.0122
100
16
71
107.0497
228.9864
258.0124
C7H7O
C9H10O2Br
C10H13O2NBr
-1.77
-3.13
-0.84
B12 25B-NBOMe-M (O-demethyl-dehydro-) isomer 2 7.4
MS1 PM at m/z 364.0540 (M+H) 3 364.0543 C17H19O3NBr -0.77
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 227.9655
FI at m/z 242.9890
57
100
13
12
91.0548
121.0653
227.9655
242.9890
C7H7
C8H9O
C8H7O2NBr
C9H10O2NBr
0
-1.98
0
0
B13 25B-NBOMe-M (O-demethyl-) isomer 1 7.6
MS1 PM at m/z 366.0700 (M+H) 4 366.0699 C17H21O3NBr 0.19
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 228.9861
FI at m/z 257.1167
FI at m/z 349.0433
58
100
0.5
1
0.6
91.0548
121.0653
228.9864
257.1178
349.0439
C7H7
C8H9O
C9H10O2Br
C16H17O3
C17H18O3Br
0
-2.81
-1.38
-4.16
-1.81
B14 25B-NBOMe-M (O-demethyl-) isomer 2 7.7
MS1 PM at m/z 366.0703 (M+H) 6 366.0699 C17H21O3NBr 1.01
MS2 FI at m/z 91.0548
FI at m/z 121.0649
FI at m/z 228.9855
FI at m/z 243.9961
FI at m/z 270.1254
59
100
0.4
0.3
0.1
91.0548
121.0653
228.9864
243.9968
270.1256
C7H7
C8H9O
C9H10O2Br
C9H11O2NBr
C17H18O3
0
-3.63
-4.00
-2.73
-0.72
B15 25B-NBOMe-M (O-demethyl-) isomer 3 8.0
MS1 PM at m/z 366.0696 (M+H) 3 366.0699 C17H21O3NBr -0.91
MS2 FI at m/z 107.0495
FI at m/z 227.9779
FI at m/z 243.0014
FI at m/z 260.0280
100
50
92
26
107.0497
227.9786
243.0021
260.0281
C7H7O
C9H9O2Br
C10H12O2Br
C10H15O2NBr
-1.77
-3.03
-2.74
-0.26
B16 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 1 5.1
MS1 PM at m/z 368.0495 (M+H) 4 368.0492 C16H19O4NBr 0.82
MS2 FI at m/z 107.0496
FI at m/z 137.0598
FI at m/z 228.9858
FI at m/z 351.0238
44
100
1
0.4
107.0497
137.0603
228.9864
351.0232
C7H7O
C8H9O2Br
C9H10O2Br
C16H16O4Br
-0.84
-3.32
-2.69
1.72
B17 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 2 5.6
MS1 PM at m/z 368.0481 (M+H) 9 368.0492 C16H19O4NBr -2.98
MS2 FI at m/z 123.0441
FI at m/z 213.9620
FI at m/z 228.9853
100
26
96
123.0446
213.9629
228.9864
C7H7O2
C8H7O2Br
C9H10O2Br
-4.10
-4.40
-4.87
4FI at m/z 246.0122 30 246.0130 C9H13O2NBr -3.11
B18 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 3 6.3
MS1 PM at m/z 368.0489 (M+H) 13 368.0492 C16H19O4NBr -0.91
MS2 FI at m/z 123.0443
FI at m/z 213.9624
FI at m/z 228.9859
FI at m/z 246.0124
100
24
72
22
123.0446
213.9629
228.9864
246.0130
C7H7O2
C8H7O2Br
C9H10O2Br
C9H13O2NBr
-2.48
-2.53
-2.25
-2.30
B19 25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 4 6.6
MS1 PM at m/z 368.0495 (M+H) 10 368.0492 C16H19O4NBr 0.82
MS2 FI at m/z 107.0495
FI at m/z 229.9573
FI at m/z 244.9808
FI at m/z 262.0074
100
61
86
33
107.0497
229.9579
244.9813
262.0073
C7H7O
C8H7O3Br
C9H10O3Br
C9H13O3NBr
-1.77
-2.42
-2.17
0.26
B20 25B-NBOMe-M (dehydro-) 7.4
MS1 PM at m/z 378.0697 (M+H) 16 378.0699 C18H21O3NBr -0.61
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 239.9647
FI at m/z 255.9966
58
100
1
8
91.0548
121.0653
239.9655
255.9968
C7H7
C8H9O
C9H7O2NBr
C10H11O2NBr
0
-2.81
-3.19
-0.65
B21 25B-NBOMe-M (O-demethyl-dehydro-hydroxy-) 5.7
MS1 PM at m/z 380.0494 (M+H) 20 380.0494 C17H19O4NBr 0.54
MS2 FI at m/z 107.0496
FI at m/z 244.9809
FI at m/z 274.0072
100
9
55
107.0497
244.9813
274.0073
C7H7O
C9H10O3Br
C10H13O3NBr
-0.84
-1.76
-0.48
B22 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 1 6.2
MS1 PM at m/z 382.0665 (M+H) 7 382.0648 C17H21O4NBr 4.33
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 228.9859
FI at m/z 365.0403
53
100
4
0.2
91.0548
121.0653
228.9864
365.0388
C7H7
C8H9O
C9H10O2Br
C10H15O3NBr
0
-2.81
-2.25
3.98
B23 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 2 6.7
MS1 PM at m/z 382.0643 (M+H) 7 382.0648 C17H21O4NBr -1.43
MS2 FI at m/z 107.0494
FI at m/z 137.0597
FI at m/z 228.9861
FI at m/z 243.9975
FI at m/z 365.0375
44
100
1
0.2
0.1
107.0497
137.0603
228.9864
243.9968
365.0388
C7H7O
C8H9O2
C9H10O2Br
C9H11O2NBr
C17H18O4Br
-2.71
-4.05
-1.38
3.01
-3.69
B24 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 3 6.8
MS1 PM at m/z 382.0644 (M+H) 11 382.0648 C17H21O4NBr -1.17
MS2 FI at m/z 123.0442
FI at m/z 227.9780
FI at m/z 243.0014
FI at m/z 260.0281
85
55
100
28
123.0446
227.9786
243.0021
260.0281
C7H7O2
C9H9O2Br
C10H12O2Br
C10H15O2NBr
-3.29
-2.59
-2.74
0
B25 25B-NBOMe-M (O-demethyl-hydroxy-) isomer 4 7.2
MS1 PM at m/z 382.0646 (M+H) 8 382.0648 C17H21O4NBr -0.65
MS2 FI at m/z 123.0442
FI at m/z 227.9779
FI at m/z 243.0014
FI at m/z 260.0280
100
56
99
28
123.0446
227.9786
243.0021
260.0281
C7H7O2
C9H9O2Br
C10H12O2Br
C10H15O2NBr
-3.29
-3.03
-2.74
-0.26
B26 25B-NBOMe-M (dehydro-hydroxy-) isomer 1 6.5
MS1 PM at m/z 394.0652 (M+H) 30 394.0648 C18H21O4NBr 0.90
MS2 FI at m/z 109.0651
FI at m/z 137.0597
FI at m/z 239.9647
FI at m/z 255.9965
100
26
1
9
109.0653
137.0603
239.9655
255.9968
C7H9O
C8H9O2
C9H7O2NBr
C10H11O2NBr
-2.20
-4.05
-3.19
-1.04
B27 25B-NBOMe-M (dehydro-hydroxy-) isomer 2 6.6
MS1 PM at m/z 394.0650 (M+H) 19 394.0648 C18H21O4NBr 0.39
5MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 256.9681
FI at m/z 271.9916
56
100
2
7
91.0548
121.0653
256.9681
271.9917
C7H7
C8H9O
C9H8O3NBr
C10H11O3NBr
0
-2.81
-0.41
-0.30
B28 25B-NBOMe-M (dehydro-hydroxy-) isomer 3 6.7
MS1 PM at m/z 394.0658 (M+H) 6 394.0648 C18H21O4NBr 2.42
MS2 FI at m/z 107.0495
FI at m/z 137.0597
FI at m/z 239.9657
FI at m/z 255.9967
38
100
1
6
107.0497
137.0603
239.9655
255.9968
C7H7O
C8H9O2
C9H7O2NBr
C10H11O3NBr
-1.77
-4.05
0.97
-0.26
B29 25B-NBOMe-M (hydroxy-) isomer 1 7.1
MS1 PM at m/z 396.0806 (M+H) 12 396.0805 C18H23O4NBr 0.26
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 243.9732
FI at m/z 258.9967
62
100
4
11
91.0548
121.0653
243.9735
258.9970
C7H7
C8H9O
C9H9O3Br
C10H12O3Br
0
-2.81
-1.25
-1.08
B30 25B-NBOMe-M (hydroxy-) isomer 2 7.3
MS1 PM at m/z 396.0800 (M+H) 17 396.0805 C18H23O4NBr -1.25
MS2 FI at m/z 109.0651
FI at m/z 137.0596
FI at m/z 243.0015
FI at m/z 258.0123
100
23
4
1
109.0653
137.0603
243.0021
258.0124
C7H9O
C8H9O2
C10H12O2Br
C10H13O2NBr
-2.20
-4.78
-2.33
-0.45
B31 25B-NBOMe-M (hydroxy-) isomer 3 7.8
MS1 PM at m/z 396.0805 (M+H) 10 396.0805 C18H23O4NBr 0
MS2 FI at m/z 107.0494
FI at m/z 137.0597
FI at m/z 243.0010
FI at m/z 258.0137
53
100
2
1
107.0497
137.0603
243.0021
258.0124
C7H7O
C8H9O2
C10H12O2Br
C10H13O2NBr
-2.71
-4.05
-4.39
4.97
B32 25B-NBOMe-M (hydroxy-) isomer 4 8.4
MS1 PM at m/z 396.0800 (M+H) 6 396.0805 C18H23O4NBr -1.25
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 258.0128
FI at m/z 378.0704
54
100
4
2
91.0548
121.0653
258.0124
378.0699
C7H7
C8H9O
C10H13O2NBr
C18H21O3NBr
0
-1.98
1.49
1.24
B33 25B-NBOMe-M (O-demethyl-bis-hydroxy-) 6.2
MS1 PM at m/z 398.0590 (M+H) 1 398.0598 C17H21O5NBr -1.91
MS2 FI at m/z 138.0312
FI at m/z 153.0547
FI at m/z 228.9861
FI at m/z 246.0123
39
100
71
25
138.0317
153.0552
228.9864
246.0124
C7H6O3
C8H9O3
C9H10O2Br
C9H13O2NBr
-3.59
-3.07
-1.38
-0.47
B34 25B-NBOMe-M (bis-hydroxy-) isomer 1 7.4
MS1 PM at m/z 412.0750 (M+H) 1 412.0754 C18H23O5NBr -1.00
MS2 FI at m/z 107.0495
FI at m/z 153.0544
FI at m/z 243.0010
FI at m/z 260.0282
54
63
100
32
107.0497
153.0552
243.0021
260.0281
C7H7O
C8H9O3
C10H12O2Br
C10H15O2NBr
-1.77
-5.03
-4.39
0.51
B35 25B-NBOMe-M (bis-hydroxy-) isomer 2 7.7
MS1 PM at m/z 412.0756 (M+H) 6 412.0754 C18H23O5NBr 0.46
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 274.9907
FI at m/z 290.0018
60
100
1
0.3
91.0548
121.0653
274.9919
290.0022
C7H7
C8H9O
C10H12O4Br
C10H13O4NBr
0
-2.81
-4.35
-1.54
16
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618 Table S2 List of 25C-NBOMe and its phase I metabolites together with the precursor mass (PM) 
19 recorded in MS1, the corresponding characteristic fragment ions (FI) in MS2, the calculated exact 
20 masses, the corresponding elemental composition, the deviation of the measured from the calculated 
21 masses, given as errors in parts per million (ppm), and the retention times (RT) in minutes (min). The 
22 metabolites were sorted by mass and RT.
No. Metabolite and characteristic ions
Measured accurate mass, m/z
Relative intensity 
in MS2, %
Calculated exact mass, 
m/z
Elemental 
composition
Error, 
ppm
RT, min
C1 25C-NBOMe 8.5
MS1 PM at m/z 336.1360 (M+H) 8 336.1361 C18H23O3NCl -0.29
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 184.0286
FI at m/z 199.0522
FI at m/z 214.0627
56
100
0.3
1
0.2
91.0548
121.0653
184.0291
199.0526
214.0629
C7H7
C8H9O
C9H9O2Cl
C10H12O2Cl
C10H13O2NCl
0
-1.98
-2.76
-1.92
-1.09
C2 25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 1 3.4
MS1 PM at m/z 202.0629 (M+H) 1 202.0629 C9H13O2NCl 0
MS2 FI at m/z 135.0441
FI at m/z 150.0676
FI at m/z 170.0129
FI at m/z 185.0365
6
23
83
100
135.0446
150.0681
170.0135
185.0369
C8H7O2
C9H10O2
C8H7O2Cl
C9H10O2Cl
-3.74
-3.20
-3.28
-2.34
C3 25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) isomer 2 3.5
MS1 PM at m/z 202.0628 (M+H) 1 202.0629 C9H13O2NCl -0.66
MS2 FI at m/z 135.0441
FI at m/z 150.0675
FI at m/z 170.0129
FI at m/z 185.0364
5
18
84
100
135.0446
150.0681
170.0135
185.0369
C8H7O2
C9H10O2
C8H7O2Cl 
C9H10O2Cl
-3.74
-3.86
-1.84
-2.88
C4 25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-deamino-carboxy-) 5.9
MS1 PM at m/z 215.0108 (M-H) 1 215.0111 C9H8O4Cl -1.46
MS2 FI at m/z 155.9976
FI at m/z 171.0210
100
2
155.9978
171.0213
C7H5O2Cl
C8H8O2Cl
-1.33
-1.65
C5 25C-NBOMe-M (N-demethoxybenzyl-) 5.2
MS1 PM at m/z 216.0781 (M+H) 1 216.0786 C10H15O2NCl -2.24
MS2 FI at m/z 164.0829
FI at m/z 169.0048
FI at m/z 184.0284
FI at m/z 199.0517
20
28
100
86
164.0837
169.0056
184.0291
199.0526
C10H12O2
C8H6O2Cl
C9H9O2Cl
C10H12O2Cl
-5.06
-4.93
-3.85
-4.44
C6 25C-NBOMe-M (N-demethoxybenzyl-oxo-) 6.6
MS1 PM at m/z 230.0581 (M+H) 1 230.0578 C10H13O3NCl 1.09
MS2 FI at m/z 155.0257
FI at m/z 173.0364
FI at m/z 185.0365
42
2
100
155.0264
173.0369
185.0369
C8H8OCl
C8H10O2Cl
C9H10O2Cl
-4.31
-3.08
-2.34
C7 25C-NBOMe-M (N-demethoxybenzyl-hydroxy-) 3.8
MS1 PM at m/z 232.0730 (M+H) 1 232.0735 C10H15O3NCl -2.15
MS2 FI at m/z 185.0000
FI at m/z 200.0234
FI at m/z 215.0469
42
30
100
185.0005
200.0240
215.0475
C8H6O3Cl
C9H9O3Cl
C10H12O3Cl
-2.96
-3.11
-2.78
C8 25C-NBOMe-M (O,O,O-tris-demethyl-) 5.0
MS1 PM at m/z 294.0879 (M+H) 6 294.0891 C15H17O3NCl -4.25
MS2 FI at m/z 107.0494
FI at m/z 136.0518
FI at m/z 171.0206
100
6
80
107.0497
136.0524
171.0213
C7H7O
C8H8O2
C8H8O2Cl
-2.71
-4.63
-3.99
7FI at m/z 188.0472 27 188.0473 C8H11O2NCl -0.44
C9 25C-NBOMe-M (O,O-bis-demethyl-dehydro-) 6.4
MS1 PM at m/z 306.0893 (M+H) 4 306.0891 C16H17O3NCl 0.49
MS2 FI at m/z 107.0495
FI at m/z 184.0160
FI at m/z 199.0395
FI at m/z 200.0474
36
46
41
100
107.0497
184.0160
199.0395
200.0473
C7H7O
C8H7O2NCl
C9H10O2NCl
C9H11O2NCl
-1.77
0
0
0.58
C10 25C-NBOMe-M (O,O-bis-demethyl-) isomer 1 5.8
MS1 PM at m/z 308.1046 (M+H) 6 308.1048 C16H19O3NCl -0.64
MS2 FI at m/z 91.0547
FI at m/z 121.0649
FI at m/z 185.0360
FI at m/z 202.0624
51
100
7
2
91.0548
121.0653
185.0369
202.0629
C7H7
C8H9O
C9H10O2Cl 
C9H13O2NCl 
-0.82
-3.63
-5.04
-2.64
C11 25C-NBOMe-M (O,O-bis-demethyl-) isomer 2 6.4
MS1 PM at m/z 308.1051 (M+H) 13 308.1048 C16H19O3NCl 0.98
MS2 FI at m/z 107.0496
FI at m/z 170.0129
FI at m/z 185.0364
FI at m/z 202.0632
100
13
77
22
107.0497
170.0135
185.0369
202.0629
C7H7O
C8H7O2Cl
C9H10O2Cl
C9H13O2NCl
-0.84
-3.28
-2.88
1.32
C12 25C-NBOMe-M (O,O-bis-demethyl-) isomer 3 6.6
MS1 PM at m/z 308.1048 (M+H) 10 308.1048 C16H19O3NCl 0
MS2 FI at m/z 107.0496
FI at m/z 170.0130
FI at m/z 185.0365
FI at m/z 202.0629
100
25
87
22
107.0497
170.0135
185.0369
202.0629
C7H7O
C8H7O2Cl
C9H10O2Cl
C9H13O2NCl
-0.84
-2.69
-2.34
0
C13 25C-NBOMe-M (O-demethyl-dehydro-) isomer 1 5.7
MS1 PM at m/z 320.1047 (M+H) 17 320.1048 C17H19O3NCl -0.31
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 198.0317
57
100
5
91.0548
121.0653
198.0316
C7H7
C8H9O
C9H9O2N
0
-1.98
-3.14
C14 25C-NBOMe-M (O-demethyl-dehydro-) isomer 2 6.4
MS1 PM at m/z 320.1049 (M+H) 24 320.1048 C17H19O3NCl 0.32
MS2 FI at m/z 107.0495
FI at m/z 185.0365
FI at m/z 214.0629
100
17
73
107.0497
185.0369
214.0629
C7H7O
C9H10O2Cl
C10H13O2NCl
-1.77
-2.34
0
C15 25C-NBOMe-M (O-demethyl-dehydro-) isomer 3 7.1
MS1 PM at m/z 320.1050 (M+H) 3 320.1048 C17H19O3NCl 0.63
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 184.0160
FI at m/z 199.0394
49
100
10
11
91.0548
121.0653
184.0160
199.0395
C7H7
C8H9O
C8H7O2NCl
C9H10O2NCl
0.27
-2.81
0
-0.29
C16 25C-NBOMe-M (O-demethyl-) isomer 1 7.2
MS1 PM at m/z 322.1206 (M+H) 10 322.1204 C17H21O3NCl 0.47
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 185.0368
FI at m/z 200.0473
FI at m/z 305.0931
54
100
1
1
0.1
91.0548
121.0653
185.0369
200.0473
305.0944
C7H7
C8H9O
C9H10O2Cl
C9H11O2NCl
C17H18O3Cl
0
-1.98
-0.72
0
-4.42
C17 25C-NBOMe-M (O-demethyl-) isomer 2 7.3
MS1 PM at m/z 322.1199 (M+H) 6 322.1204 C17H21O3NCl -1.70
MS2 FI at m/z 91.0549
FI at m/z 121.0651
FI at m/z 185.0364
FI at m/z 200.0473
FI at m/z 305.0934
58
100
0.3
0.2
0.1
91.0548
121.0653
185.0369
200.0473
305.0944
C7H7
C8H9O
C9H10O2Cl
C9H11O2NCl
C17H18O3Cl
1.37
-1.98
-2.88
0
-3.44
C18 25C-NBOMe-M (O-demethyl-) isomer 3 7.7
MS1 PM at m/z 322.1198 (M+H) 10 322.1204 C17H21O3NCl -2.01
8MS2 FI at m/z 107.0494
FI at m/z 184.0285
FI at m/z 199.0518
FI at m/z 216.0784
100
44
90
21
107.0497
184.0291
199.0526
216.0786
C7H7O
C9H9O2Cl
C10H12O2Cl
C10H15O2NCl
-2.71
-3.30
-3.93
-0.85
C19 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 1 5.0
MS1 PM at m/z 324.1006 (M+H) 4 324.0997 C16H19O4NCl 2.73
MS2 FI at m/z 107.0495
FI at m/z 137.0597
FI at m/z 185.0365
FI at m/z 202.0637
FI at m/z 307.0722
44
100
4
1
1
107.0497
137.0603
185.0369
202.0629
307.0737
C7H7O
C8H9O2Cl
C9H10O2Cl
C19H13O2NCl
C16H16O4Cl
-1.77
-4.05
-2.34
3.79
-4.93
C20 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 2 5.3
MS1 PM at m/z 324.0997 (M+H) 12 324.0997 C16H19O4NCl 0
MS2 FI at m/z 123.0443
FI at m/z 170.0129
FI at m/z 185.0365
FI at m/z 202.0630
95
19
100
26
123.0446
170.0135
185.0369
202.0635
C7H7O2
C8H7O2Cl
C9H10O2Cl
C9H13O2NCl
-2.48
-3.28
-2.34
-2.39
C21 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 3 5.6
MS1 PM at m/z 324.0995 (M+H) 3 324.0997 C16H19O4NCl -0.66
MS2 FI at m/z 107.0495
FI at m/z 186.0078
FI at m/z 201.0312
FI at m/z 218.0578
100
41
94
31
107.0497
186.0084
201.0318
218.0578
C7H7O
C8H7O3Cl
C9H10O3Cl
C9H13O3NCl
-1.77
-3.08
-3.22
0
C22 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 4 5.8
MS1 PM at m/z 324.0995 (M+H) 11 324.0997 C16H19O4NCl -0.66
MS2 FI at m/z 123.0443
FI at m/z 170.0130
FI at m/z 185.0365
FI at m/z 202.0628
100
12
65
17
123.0446
170.0135
185.0369
202.0635
C7H7O2
C8H7O2Cl
C9H10O2Cl
C9H13O2NCl
-2.48
-2.69
-2.34
-3.38
C23 25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) isomer 5 6.2
MS1 PM at m/z 324.0990 (M+H) 1 324.0997 C16H19O4NCl -2.20
MS2 FI at m/z 107.0495
FI at m/z 200.0473
FI at m/z 218.0581
FI at m/z 306.0890
100
99
1
9
107.0497
200.0473
218.0578
306.0891
C7H7O
C9H11O2NCl
C9H13O3NCl
C16H17O3NCl
-1.77
0
1.15
-0.49
C24 25C-NBOMe-M (dehydro-) 7.2
MS1 PM at m/z 334.1202 (M+H) 20 334.1204 C18H21O3NCl -0.74
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 196.0160
FI at m/z 212.0472
53
100
1
7
91.0548
121.0653
196.0160
212.0473
C7H7
C8H9O
C9H7O2NCl
C10H11O2NCl
0
-1.98
0
-0.39
C25 25C-NBOMe-M (O-demethyl-dehydro-hydroxy-) 6.0
MS1 PM at m/z 336.0983 (M+H) 3 336.0997 C17H19O4NCl -4.21
MS2 FI at m/z 107.0495
FI at m/z 137.0597
FI at m/z 184.0160
FI at m/z 199.0394
42
100
11
11
107.0497
137.0603
184.0160
199.0395
C7H7O
C8H9O2
C8H7O2NCl
C9H10O2NCl
-1.77
-4.05
0
-0.29
C26 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 1 6.1
MS1 PM at m/z 338.1145 (M+H) 9 338.1154 C17H21O4NCl -2.55
MS2 FI at m/z 107.0495
FI at m/z 200.0235
FI at m/z 215.0469
FI at m/z 232.0733
100
78
86
26
107.0497
200.0240
215.0475
232.0735
C7H7O
C9H9O3Cl
C10H12O3Cl
C10H15O3NCl
-1.77
-3.32
-2.78
-0.86
C27 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 2 6.4
MS1 PM at m/z 338.1151 (M+H) 7 338.1154 C17H21O4NCl -0.78
MS2 FI at m/z 107.0495
FI at m/z 137.0598
FI at m/z 185.0365
FI at m/z 200.0465
41
100
1
0.2
107.0497
137.0603
185.0369
200.0473
C7H7O
C8H9O2
C9H10O2Cl
C9H11O2NCl
-1.77
-3.32
-2.34
-3.92
9FI at m/z 321.0878 0.2 321.0894 C17H18O4Cl -4.87
C28 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 3 6.5
MS1 PM at m/z 338.1146 (M+H) 10 338.1154 C17H21O4NCl -2.26
MS2 FI at m/z 123.0442
FI at m/z 184.0286
FI at m/z 199.0521
FI at m/z 216.0788
100
47
91
22
123.0446
184.0291
199.0526
216.0786
C7H7O2
C9H9O2Cl
C10H12O2Cl
C10H15O2NCl
-3.29
-2.76
-2.43
1.00
C29 25C-NBOMe-M (O-demethyl-hydroxy-) isomer 4 7.1
MS1 PM at m/z 338.1164 (M+H) 5 338.1154 C17H21O4NCl 3.07
MS2 FI at m/z 123.0443
FI at m/z 184.0287
FI at m/z 199.0521
FI at m/z 216.0786
100
39
76
15
123.0446
184.0291
199.0526
216.0786
C7H7O2
C9H9O2Cl
C10H12O2Cl
C10H15O2NCl
-2.48
-2.22
-2.43
0
C30 25C-NBOMe-M (dehydro-hydroxy-) 6.3
MS1 PM at m/z 350.1148 (M+H) 17 350.1154 C18H21O4NCl -1.61
MS2 FI at m/z 91.0547
FI at m/z 121.0649
FI at m/z 213.0185
FI at m/z 228.0421
54
100
2
6
91.0548
121.0653
213.0187
228.0422
C7H7
C8H9O
C9H8O3NCl
C10H11O3NCl
-0.82
-3.63
-1.05
-0.43
C31 25C-NBOMe-M (hydroxy-) isomer 1 6.9
MS1 PM at m/z 352.1303 (M+H) 10 352.1310 C18H23O4NCl -2.03
MS2 FI at m/z 91.0546
FI at m/z 121.0649
FI at m/z 200.0231
FI at m/z 215.0465
51
100
2
2
91.0548
121.0653
200.0240
215.0475
C7H7
C8H9O
C9H9O3Cl
C10H12O3Cl
-1.92
-3.63
-4.61
-4.64
C32 25C-NBOMe-M (hydroxy-) isomer 2 7.1
MS1 PM at m/z 352.1304 (M+H) 13 352.1310 C18H23O4NCl -1.74
MS2 FI at m/z 91.0549
FI at m/z 121.0651
FI at m/z 200.0236
FI at m/z 215.0472
61
100
3
10
91.0548
121.0653
200.0240
215.0475
C7H7
C8H9O
C9H9O3Cl
C10H12O3Cl
1.37
-1.98
-2.11
-1.39
C33 25C-NBOMe-M (hydroxy-) isomer 3 7.6
MS1 PM at m/z 352.1305 (M+H) 9 352.1310 C18H23O4NCl -1.46
MS2 FI at m/z 107.0494
FI at m/z 137.0596
FI at m/z 184.0283
FI at m/z 199.0520
43
100
2
5
107.0497
137.0603
184.0291
199.0526
C7H7O
C8H9O2
C9H9O2Cl
C10H12O2Cl
-2.71
-4.78
-4.39
-2.93
C34 25C-NBOMe-M (O-demethyl-bis-hydroxy-) 5.7
MS1 PM at m/z 354.1090 (M+H) 2 354.1103 C17H21O5NCl -3.61
MS2 FI at m/z 107.0494
FI at m/z 153.0550
FI at m/z 185.0362
FI at m/z 202.0629
60
60
100
23
107.0497
153.0552
185.0369
202.0629
C7H7O
C8H9O3
C9H10O2Cl
C9H13O2NCl
-2.71
-1.11
-3.96
0
C35 25C-NBOMe-M (bis-hydroxy-) isomer 1 6.0
MS1 PM at m/z 368.1241 (M+H) 6 368.1259 C18H23O5NCl -4.97
MS2 FI at m/z 107.0495
FI at m/z 137.0597
FI at m/z 215.0467
FI at m/z 230.0570
40
100
1
1
107.0497
137.0603
215.0475
230.0578
C7H7O
C8H9O2
C10H12O3Cl
C10H13O3NCl
-1.77
-4.05
-3.71
-3.69
C36 25C-NBOMe-M (bis-hydroxy-) isomer 2 6.9
MS1 PM at m/z 368.1247 (M+H) 1 368.1259 C18H23O5NCl -3.34
MS2 FI at m/z 107.0495
FI at m/z 153.0546
FI at m/z 199.0521
FI at m/z 216.0782
48
58
100
17
107.0497
153.0552
199.0526
216.0786
C7H7O
C8H9O3
C10H12O2Cl
C10H15O2NCl
-1.77
-3.72
-2.43
-1.78
23
10
24 Table S3 List of all 25B-NBOMe phase II metabolites together with the precursor mass (PM) 
25 recorded in MS1, the corresponding characteristic fragment ions (FI) in MS2, the calculated exact 
26 masses, the corresponding elemental composition, the deviation of the measured from the calculated 
27 masses, given as errors in parts per million (ppm), and the retention times (RT) in minutes (min). The 
28 metabolites were sorted by mass and RT. Numbering according to Table 1 (AC = N-acetylation, GSH 
29 = glutathione conjugation, ME = O-methylation, G = glucuronidation, S = sulfation, AC+G = 
30 acetylation combined with glururonidation, AC+S = acetylation combined with sulfation)
No. Metabolite and characteristic ions
Measured accurate mass, m/z
Relative intensity 
in MS2, %
Calculated exact mass, 
m/z
Elemental 
composition
Error, 
ppm
RT, min
B3
AC
25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 1 6.6
MS1 PM at m/z 288.0226 (M+H) 5 288.0230 C11H15O3NBr -1.32
MS2 FI at m/z 150.0674
FI at m/z 213.9621
FI at m/z 228.9857
FI at m/z 246.0123
58
35
100
13
150.0681
213.9629
228.9864
246.0124
C9H10O2
C8H7O2Br
C9H10O2Br
C9H13O2NBr
-4.53
-3.93
-3.13
-0.47
B4
AC
25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 2 6.7
MS1 PM at m/z 288.0226 (M+H) 6 288.0230 C11H15O3NBr -1.32
MS2 FI at m/z 150.0674
FI at m/z 213.9621
FI at m/z 228.9857
FI at m/z 246.0123
32
64
100
13
150.0681
213.9629
228.9864
246.0124
C9H10O2
C8H7O2Br
C9H10O2Br
C9H13O2NBr
-4.53
-3.93
-3.13
-0.47
B3
AC+S
25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl sulfate isomer 1 5.4
MS1 PM at m/z 367.9798 (M+H) 4 367.9798 C11H15O6NBrS 0
MS2 FI at m/z 228.9858
FI at m/z 246.0125
FI at m/z 288.0229
FI at m/z 308.9424
FI at m/z 325.9692
100
8
7
24
18
228.9864
246.0124
288.0230
308.9432
325.9692
C9H10O2Br
C9H13O2NBr
C11H15O3NBr
C9H10O5BrS
C9H13O5NBrS
-2.69
0.34
-0.28
-2.70
0
B4
AC+S
25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl sulfate isomer 2 5.5
MS1 PM at m/z 367.9798 (M+H) 4 367.9798 C11H15O6NBrS 0
MS2 FI at m/z 228.9858
FI at m/z 246.0123
FI at m/z 288.0226
FI at m/z 308.9425
FI at m/z 325.9692
100
12
11
16
17
228.9864
246.0124
288.0230
308.9432
325.9692
C9H10O2Br
C9H13O2NBr
C11H15O3NBr
C9H10O5BrS
C9H13O5NBrS
-2.69
-0.47
-1.32
-2.37
0
B8
GSH-1
25B-NBOMe-M (O,O-bis-demethyl-) S-methyl 7.7
MS1 PM at m/z 398.0405 (M+H) 1 398.0420 C17H21O3NBrS -3.78
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 259.9503
FI at m/z 381.0149
53
100
6
0.4
91.0548
121.0653
259.9507
381.0160
C7H7
C8H9O
C9H9O2BrS
C17H18O3BrS
0
-2.81
-1.40
-2.84
B33
ME
25B-NBOMe-M (O-demethyl-bis-hydroxy-) O-methyl 6.8
MS1 PM at m/z 412.0760 (M+H) 1 412.0754 C18H23O5NBr 1.43
MS2 FI at m/z 137.0597
FI at m/z 167.0704
FI at m/z 228.9859
FI at m/z 246.0125
39
100
18
6
137.0603
167.0708
228.9864
246.0124
C8H9O2
C9H11O3
C9H10O2Br
C9H13O2NBr
-4.05
-2.51
-2.25
0.34
B7
S
25B-NBOMe-M (O,O,O-tris-demethyl-) sulfate 4.7
MS1 PM at m/z 417.9959 (M+H) 6 417.9954 C15H17O6NBrS 1.08
11
MS2 FI at m/z 107.0496
FI at m/z 214.9702
FI at m/z 294.9271
FI at m/z 311.9538
FI at m/z 338.0387
100
80
18
27
10
107.0497
214.9708
294.9276
311.9536
338.0386
C7H7O
C8H8O2Br
C8H8O5BrS
C8H11O5NBrS
C15H17O3NBr
-0.84
-2.63
-1.64
0.69
0.20
B3/4
G
25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) glucuronide 3.0
MS1 PM at m/z 422.0446 (M+H) 4 422.0445 C15H21O8NBr 0.22
MS2 FI at m/z 150.0674
FI at m/z 213.9623
FI at m/z 228.9858
FI at m/z 246.0126
24
43
100
28
150.0681
213.9629
228.9864
246.0124
C9H10O2
C8H7O2Br
C9H10O2Br
C9H13O2NBr
-3.86
-3.00
-2.69
0.75
B8
S
25B-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 1 6.0
MS1 PM at m/z 432.0113 (M+H) 2 432.0111 C16H19O6NBrS 0.47
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 352.0541
61
100
2
91.0548
121.0653
352.0543
C7H7
C8H9O
C16H19O3NBr
0
-2.81
-0.52
B9/10
S
25B-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 2 6.8
MS1 PM at m/z 432.0120 (M+H) 24 432.0111 C16H19O6NBrS 2.09
MS2 FI at m/z 107.0496
FI at m/z 228.9860
FI at m/z 308.9428
FI at m/z 325.9696
FI at m/z 352.0546
99
100
34
38
5
107.0497
228.9864
308.9432
325.9692
352.0543
C7H7O
C9H10O2Br
C9H10O5BrS
C9H13O5NBrS
C16H19O3NBr
-0.84
-1.82
-1.40
1.12
0.90
B13/14
S
25B-NBOMe-M (O-demethyl-) sulfate isomer 1 7.6
MS1 PM at m/z 446.0268 (M+H) 2 446.0267 C17H21O6NBrS 0.12
MS2 FI at m/z 91.0549
FI at m/z 121.0651
FI at m/z 349.0431
FI at m/z 366.0703
60
100
1
4
91.0548
121.0653
349.0439
366.0699
C7H7
C8H9O
C17H18O3Br
C17H21O3NBr
1.37
-1.98
-2.38
1.01
B15
S
25B-NBOMe-M (O-demethyl-) sulfate isomer 2 8.5
MS1 PM at m/z 446.0264 (M+H) 3 446.0267 C17H21O6NBrS -0.78
MS2 FI at m/z 107.0495
FI at m/z 243.0015
FI at m/z 260.0282
FI at m/z 366.0702
59
100
20
30
107.0497
243.0021
260.0281
366.0699
C7H7O
C10H12O2Br
C10H15O2NBr
C17H21O3NBr
-1.77
-2.33
0.51
0.73
B16
S
25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) sulfate isomer 1 4.8
MS1 PM at m/z 448.0061 (M+H) 5 448.0060 C16H19O7NBrS 0.19
MS2 FI at m/z 107.0496
FI at m/z 137.0598
FI at m/z 217.0164
FI at m/z 368.0491
41
100
15
5
107.0497
137.0603
217.0171
368.0492
C7H7O
C8H9O2
C8H9O5S
C16H19O4NBr
-0.84
-3.32
-3.10
-0.26
B17/18
S
25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) sulfate isomer 2 5.6
MS1 PM at m/z 448.0052 (M+H) 3 448.0060 C16H19O7NBrS -1.82
MS2 FI at m/z 123.0443
FI at m/z 228.9860
FI at m/z 308.9426
FI at m/z 325.9695
FI at m/z 368.0499
86
100
32
38
5
123.0446
228.9864
308.9432
325.9692
368.0492
C7H7O2
C9H10O2Br
C9H10O5BrS
C9H13O5NBrS
C16H19O4NBr
-2.48
-1.82
-2.05
0.82
1.91
B22
S
25B-NBOMe-M (O-demethyl-hydroxy-) sulfate isomer 1 6.2
MS1 PM at m/z 462.0212 (M+H) 2 462.0217 C17H21O7NBrS -1.00
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 258.9974
FI at m/z 382.0654
65
100
1
4
91.0548
121.0653
258.9970
382.0648
C7H7
C8H9O
C10H12O3Br
C17H21O4NBr
1.37
-2.81
1.62
1.45
B24/25
S
25B-NBOMe-M (O-demethyl-hydroxy-) sulfate isomer 2 7.2
MS1 PM at m/z 462.0215 (M+H) 9 462.0217 C17H21O7NBrS -0.35
MS2 FI at m/z 123.0442
FI at m/z 203.0007
FI at m/z 243.0014
58
9
100
123.0446
203.0014
243.0021
C7H7O2
C7H7O5S
C10H12O2Br
-3.29
-3.56
-2.74
12
FI at m/z 260.0282
FI at m/z 382.0640
19
11
260.0281
382.0648
C10H15O2NBr
C17H21O4NBr
0.51
-2.22
B3/4
AC+G
25B-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl glucuronide 5.3
MS1 PM at m/z 464.0564 (M+H) 1 464.0551 C17H23O9NBr 2.86
MS2 FI at m/z 150.0674
FI at m/z 228.9858
FI at m/z 246.0121
FI at m/z 288.0225
18
100
20
41
150.0681
228.9864
246.0124
288.0230
C9H10O2
C9H10O2Br
C9H13O2NBr
C11H15O3NBr
-4.53
-2.69
-1.29
-1.67
B8
GSH-2
25B-NBOMe-M (O,O-bis-demethyl-) acetylcysteine 6.4
MS1 PM at m/z 513.0695 (M+H) 10 513.0689 C21H26O6N2BrS 1.08
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 384.0264
FI at m/z 407.0273
60
100
6
1
91.0548
121.0653
384.0264
407.0271
C7H7
C8H9O
C16H19O3NBrS
C14H20O5N2BrS
0
-2.81
0
0.53
B7
G
25B-NBOMe-M (O,O,O-tris-demethyl-) glucuronide 4.0
MS1 PM at m/z 514.0714 (M+H) 5 514.0707 C21H25O9NBr 1.32
MS2 FI at m/z 107.0495
FI at m/z 214.9701
FI at m/z 338.0383
FI at m/z 408.0289
71
100
24
10
107.0497
214.9708
338.0386
408.0289
C7H7O
C8H8O2Br
C15H17O3NBr
C14H19O8NBr
-1.77
-3.10
-0.98
0
B8
G
25B-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 1 4.8
MS1 PM at m/z 528.0867 (M+H) 5 528.0864 C22H27O9NBr 0.62
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 352.0544
47
100
16
91.0548
121.0653
352.0543
C7H7
C8H9O
C16H19O3NBr
0
-2.81
0.34
B9/10
G
25B-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 2 5.9
MS1 PM at m/z 528.0872 (M+H) 5 528.0864 C22H27O9NBr 1.57
MS2 FI at m/z 107.0496
FI at m/z 228.9860
FI at m/z 246.0127
FI at m/z 352.0548
FI at m/z 422.0448
60
100
32
26
7
107.0497
228.9864
246.0124
352.0543
422.0445
C7H7O
C9H10O2Br
C9H13O2NBr
C16H19O3NBr
C15H21O8NBr
-0.84
-1.82
1.15
1.47
0.70
B13
G
25B-NBOMe-M (O-demethyl-) glucuronide isomer 1 5.6
MS1 PM at m/z 542.1024 (M+H) 9 542.1020 C23H29O9NBr 0.70
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 228.9858
FI at m/z 366.0705
57
100
1
12
91.0548
121.0653
228.9864
366.0699
C7H7
C8H9O
C9H10O2Br
C17H21O3NBr
0
-2.81
-2.69
1.55
B14
G
25B-NBOMe-M (O-demethyl-) glucuronide isomer 2 6.6
MS1 PM at m/z 542.1022 (M+H) 4 542.1020 C23H29O9NBr 0.33
MS2 FI at m/z 91.0549
FI at m/z 121.0651
FI at m/z 228.9856
FI at m/z 366.0699
56
100
1
21
91.0548
121.0653
228.9864
366.0699
C7H7
C8H9O
C9H10O2Br
C17H21O3NBr
1.37
-1.98
-3.56
0
B15
G
25B-NBOMe-M (O-demethyl-) glucuronide isomer 3 7.3
MS1 PM at m/z 542.1020 (M+H) 8 542.1020 C23H29O9NBr 0
MS2 FI at m/z 107.0495
FI at m/z 243.0015
FI at m/z 260.0282
FI at m/z 366.0704
100
45
14
21
107.0497
243.0021
260.0281
366.0699
C7H7O
C10H12O2Br
C10H15O2NBr
C17H21O3NBr
-1.77
-2.33
0.51
1.28
B16
G
25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) glucuronide isomer 1 4.1
MS1 PM at m/z 544.0806 (M+H) 4 544.0813 C22H27O10NBr -1.26
MS2 FI at m/z 107.0495
FI at m/z 137.0597
FI at m/z 368.0493
36
100
12
107.0497
137.0603
368.0492
C7H7O
C8H9O2
C16H19O4NBr
-1.77
-4.05
0.28
B19
G
25B-NBOMe-M (O,O-bis-demethyl-hydroxy-) glucuronide isomer 2 5.3
MS1 PM at m/z 544.0817 (M+H) 4 544.0813 C22H27O10NBr 0.76
13
MS2 FI at m/z 107.0495
FI at m/z 244.9808
FI at m/z 262.0074
FI at m/z 368.0493
FI at m/z 438.0394
52
100
35
31
3
107.0497
244.9813
262.0073
368.0492
438.0394
C7H7O
C9H10O3Br
C9H13O3NBr
C16H19O4NBr
C15H21O9NBr
-1.77
-2.17
0.26
0.28
0
B23
G
25B-NBOMe-M (O-demethyl-hydroxy-) glucuronide isomer 1 5.7
MS1 PM at m/z 558.0969 (M+H) 4 558.0969 C23H29O10NBr 0
MS2 FI at m/z 107.0495
FI at m/z 137.0597
FI at m/z 228.9856
FI at m/z 382.0645
36
100
1
18
107.0497
137.0603
228.9864
382.0648
C7H7O
C8H9O2
C9H10O2Br
C17H21O4NBr
-1.77
-4.05
-2.25
-0.38
B22
G
25B-NBOMe-M (O-demethyl-hydroxy-) glucuronide isomer 2 5.9
MS1 PM at m/z 558.0970 (M+H) 5 558.0969 C23H29O10NBr 0.11
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 382.0647
48
100
22
91.0548
121.0653
382.0648
C7H7
C8H9O
C17H21O4NBr
0
-2.81
-0.38
B24/25
G
25B-NBOMe-M (O-demethyl-hydroxy-) glucuronide isomer 3 6.0
MS1 PM at m/z 558.0968 (M+H) 8 558.0969 C23H29O10NBr -0.24
MS2 FI at m/z 123.0443
FI at m/z 243.0019
FI at m/z 260.0282
FI at m/z 299.0758
FI at m/z 382.0663
84
100
32
2
5
123.0446
243.0021
260.0281
299.0767
382.0648
C7H7O2
C10H12O2Br
C10H15O2NBr
C13H15O8
C17H21O4NBr
-2.48
-0.68
0.51
-2.99
3.80
B30
G
25B-NBOMe-M (hydroxy-) glucuronide isomer 1 6.6
MS1 PM at m/z 572.1151 (M+H) 7 572.1126 C24H31O10NBr 4.39
MS2 FI at m/z 109.0653
FI at m/z 137.0598
FI at m/z 313.0920
FI at m/z 396.0792
100
37
30
5
109.0653
137.0603
313.0923
396.0805
C7H9O
C8H9O2
C14H17O8
C18H23O4NBr
-0.37
-3.32
-1.10
-3.27
B31
G
25B-NBOMe-M (hydroxy-) glucuronide isomer 2 6.9
MS1 PM at m/z 572.1134 (M+H) 4 572.1126 C24H31O10NBr 1.42
MS2 FI at m/z 107.0496
FI at m/z 137.0599
FI at m/z 313.0918
FI at m/z 396.0808
24
100
26
4
107.0497
137.0603
313.0923
396.0805
C7H7O
C8H9O2
C14H17O8
C18H23O4NBr
-0.84
-2.59
-1.74
0.77
31
14
32 Table S4 List of all 25C-NBOMe phase II metabolites together with the precursor mass (PM) 
33 recorded in MS1, the corresponding characteristic fragment ions (FI) in MS2, the calculated exact 
34 masses, the corresponding elemental composition, the deviation of the measured from the calculated 
35 masses, given as errors in parts per million (ppm), and the retention times (RT) in minutes (min). The 
36 metabolites were sorted by mass and RT. Numbering according to Table 2 (AC = N-acetylation, GSH 
37 = glutathione conjugation, ME = O-methylation, G = glucuronidation, S = sulfation, AC+G = 
38 acetylation combined with glururonidation, AC+S = acetylation combined with sulfation)
No. Metabolite and characteristic ions
Measured accurate mass, m/z
Relative intensity 
in MS2, %
Calculated exact mass, 
m/z
Elemental 
composition
Error, 
ppm
RT, min
C2
AC
25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 1 6.3
MS1 PM at m/z 244.0736 (M+H) 3 244.0735 C11H15O3NCl 0.42
MS2 FI at m/z 150.0676
FI at m/z 170.0130
FI at m/z 185.0365
FI at m/z 202.0630
25
30
100
9
150.0681
170.0135
185.0369
202.0629
C9H10O2
C8H7O2Cl
C9H10O2Cl
C9H13O2NCl
-3.20
-2.69
-2.34
0.33
C3
AC
25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl isomer 2 6.5
MS1 PM at m/z 244.0732 (M+H) 4 244.0735 C11H15O3NCl -1.22
MS2 FI at m/z 150.0676
FI at m/z 170.0129
FI at m/z 185.0365
FI at m/z 202.0629
12
48
100
11
150.0681
170.0135
185.0369
202.0629
C9H10O2
C8H7O2Cl
C9H10O2Cl
C9H13O2NCl
-3.20
-3.28
-2.34
0
C7
AC
25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-hydroxy-) N-acetyl 5.1
MS1 PM at m/z 260.0681 (M+H) 4 260.0684 C11H15O4NCl -1.21
MS2 FI at m/z 166.0625
FI at m/z 186.0078
FI at m/z 201.0312
FI at m/z 218.0577
7
82
100
14
166.0630
186.0084
201.0318
218.0578
C9H10O3
C8H7O3Cl
C9H10O3Cl
C9H13O3NCl
-2.98
-3.08
-3.22
-0.68
C3/4
AC+S
25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl sulfate 5.1
MS1 PM at m/z 324.0305 (M+H) 4 324.0303 C11H15O6NClS 0.57
MS2 FI at m/z 185.0365
FI at m/z 202.0628
FI at m/z 244.0736
FI at m/z 264.9933
FI at m/z 282.0199
100
8
7
26
18
185.0369
202.0629
244.0735
264.9938
282.0198
C9H10O2Cl
C9H13O2NCl
C11H15O3NCl
C9H10O5ClS
C9H13O5NClS
-2.34
-0.66
0.42
-1.70
0.53
C10
GSH-1
25C-NBOMe-M (O,O-bis-demethyl-) S-methyl 7.5
MS1 PM at m/z 354.0922 (M+H) 6 354.0925 C17H21O3NClS -0.91
MS2 FI at m/z 91.0547
FI at m/z 121.0650
FI at m/z 232.0197
FI at m/z 337.0650
55
100
0.5
0.5
91.0548
121.0653
232.0194
337.0665
C7H7
C8H9O
C9H11O2NClS
C17H18O3ClS
-0.82
-2.81
1.48
-4.51
C34
ME
25C-NBOMe-M (O-demethyl-bis-hydroxy-) O-methyl 6.5
MS1 PM at m/z 368.1250 (M+H) 1 368.1259 C18H23O5NCl -2.52
MS2 FI at m/z 137.0597
FI at m/z 167.0704
FI at m/z 185.0362
FI at m/z 202.0631
40
100
14
2
137.0603
167.0708
185.0369
202.0629
C8H9O2
C9H11O3
C9H10O2Cl
C9H13O2NCl
-4.05
-2.51
-3.96
0.82
C8
S
25C-NBOMe-M (O,O,O-tris-demethyl-) sulfate 4.5
15
MS1 PM at m/z 374.0463 (M+H) 7 374.0460 C15H17O6NClS 0.89
MS2 FI at m/z 107.0496
FI at m/z 171.0210
FI at m/z 250.9778
FI at m/z 268.0043
FI at m/z 294.0894
100
78
21
26
10
107.0497
171.0213
250.9781
268.0041
294.0891
C7H7O
C8H8O2Cl
C8H8O5ClS
C8H11O5NClS
C15H17O3NCl
-0.84
-1.65
-1.20
0.74
0.85
C2/3
G
25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) glucuronide 2.6
MS1 PM at m/z 378.0949 (M+H) 5 378.0950 C15H21O8NCl -0.33
MS2 FI at m/z 150.0675
FI at m/z 170.0130
FI at m/z 185.0365
FI at m/z 202.0628
9
35
100
24
150.0681
170.0135
185.0369
202.0629
C9H10O2
C8H7O2Cl
C9H10O2Cl
C9H13O2NCl
-3.86
-2.69
-2.34
-0.66
C36
ME
25C-NBOMe-M (bis-hydroxy-) O-methyl 7.6
MS1 PM at m/z 382.1410 (M+H) 1 382.1416 C19H25O5NCl -1.51
MS2 FI at m/z 137.0596
FI at m/z 167.0702
FI at m/z 199.0519
FI at m/z 216.0785
39
100
22
6
137.0603
167.0708
199.0526
216.0786
C8H9O2
C9H11O3
C10H12O2Cl
C10H15O2NCl
-4.78
-3.71
-3.43
-0.39
C10
S
25C-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 1 5.8
MS1 PM at m/z 388.0614 (M+H) 2 388.0616 C16H19O6NClS -0.56
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 308.1046
54
100
2
91.0548
121.0653
308.1048
C7H7
C8H9O
C16H19O3NCl
0
-2.81
-0.64
C11
S
25C-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 2 6.6
MS1 PM at m/z 388.0617 (M+H) 6 388.0616 C16H19O6NClS 0.22
MS2 FI at m/z 107.0496
FI at m/z 185.0366
FI at m/z 264.9934
FI at m/z 282.0200
FI at m/z 308.1047
96
100
40
42
6
107.0497
185.0369
264.9938
282.0198
308.1048
C7H7O
C9H10O2Cl
C9H10O5ClS
C9H13O5NClS
C16H19O3NCl
-0.84
-1.80
-1.32
0.88
-0.32
C12
S
25C-NBOMe-M (O,O-bis-demethyl-) sulfate isomer 3 7.0
MS1 PM at m/z 388.0619 (M+H) 11 388.0616 C16H19O6NClS 0.73
MS2 FI at m/z 107.0496
FI at m/z 185.0366
FI at m/z 187.0060
FI at m/z 202.0629
FI at m/z 308.1048
100
99
6
28
37
107.0497
185.0369
187.0065
202.0629
308.1048
C7H7O
C9H10O2Cl
C7H7O4S
C9H13O5NClS
C16H19O3NCl
-0.84
-1.80
-2.71
0
0
C16/17
S
25C-NBOMe-M (O-demethyl-) sulfate isomer 1 7.4
MS1 PM at m/z 402.0778 (M+H) 3 402.0773 C17H21O6NClS 1.33
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 305.0938
FI at m/z 322.1205
61
100
1
4
91.0548
121.0653
305.0944
322.1204
C7H7
C8H9O
C17H18O3Cl
C17H21O3NCl
0
-1.98
-2.12
0.16
C18
S
25C-NBOMe-M (O-demethyl-) sulfate isomer 2 8.2
MS1 PM at m/z 402.0785 (M+H) 5 402.0773 C17H21O6NClS 3.07
MS2 FI at m/z 107.0495
FI at m/z 199.0521
FI at m/z 216.0787
FI at m/z 322.1205
59
100
19
32
107.0497
199.0526
216.0786
322.1204
C7H7O
C10H12O2Cl
C10H15O2NCl
C17H21O3NCl
-1.77
-2.43
0.54
0.16
C20
S
25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) sulfate 5.0
MS1 PM at m/z 404.0569 (M+H) 9 404.0565 C16H19O7NClS 0.91
MS2 FI at m/z 123.0443
FI at m/z 185.0365
FI at m/z 264.9934
FI at m/z 282.0200
FI at m/z 324.0998
80
100
26
22
8
123.0446
185.0369
264.9938
282.0198
324.0997
C7H7O2
C9H10O2Cl
C9H10O5ClS
C9H13O5NClS
C16H19O4NCl
-2.48
-2.34
-1.32
0.88
0.27
C22
S
25C-NBOMe-M (O-demethyl-hydroxy-) sulfate 6.9
MS1 PM at m/z 418.0726 (M+H) 12 418.0722 C17H21O7NClS 1.00
MS2 FI at m/z 123.0443 55 123.0446 C7H7O2 -2.48
16
FI at m/z 199.0522 
FI at m/z 203.0008
FI at m/z 216.0788
FI at m/z 338.1154
100
10
17
11
199.0526
203.0014
216.0786
338.1154
C10H12O2Cl
C7H7O5S
C10H15O2NCl
C17H21O4NCl
-1.92
-3.06
1.00
0
C2/3
AC+G
25C-NBOMe-M (N-demethoxybenzyl-O-demethyl-) N-acetyl glucuronide 5.0
MS1 PM at m/z 420.1060 (M+H) 1 420.1056 C17H23O9NCl 0.98
MS2 FI at m/z 150.0675
FI at m/z 185.0365
FI at m/z 202.0628
FI at m/z 244.0736
6
100
19
36
150.0681
185.0369
202.0629
244.0735
C9H10O2
C9H10O2Cl
C9H13O2NCl
C11H15O3NCl
-3.86
-2.34
-0.66
0.42
C10
GSH-2
25C-NBOMe-M (O,O-bis-demethyl-) acetylcysteine 6.2
MS1 PM at m/z 469.1200 (M+H) 14 469.1195 C21H26O6N2ClS 1.14
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 340.0770
FI at m/z 363.0781
55
100
6
0.5
91.0548
121.0653
340.0769
363.0776
C7H7
C8H9O
C16H19O3NClS
C14H20O5N2ClS
0
-2.81
0.38
1.38
C8
G
25C-NBOMe-M (O,O,O-tris-demethyl-) glucuronide 3.8
MS1 PM at m/z 470.1219 (M+H) 8 470.1212 C21H25O9NCl 1.41
MS2 FI at m/z 107.0495
FI at m/z 171.0208
FI at m/z 294.0891
FI at m/z 364.0796
69
100
28
12
107.0497
171.0213
294.0891
364.0794
C7H7O
C8H8O2Cl
C15H17O3NCl
C14H19O8NCl
-1.77
-2.82
0
0.62
C10
G
25C-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 1 4.6
MS1 PM at m/z 484.1377 (M+H) 10 484.1369 C22H27O9NCl 1.68
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 308.1047
41
100
18
91.0548
121.0653
308.1048
C7H7
C8H9O
C16H19O3NCl
0
-1.98
-0.32
C11
G
25C-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 2 5.5
MS1 PM at m/z 484.1375 (M+H) 23 484.1369 C22H27O9NCl 1.26
MS2 FI at m/z 107.0495
FI at m/z 185.0365
FI at m/z 202.0629
FI at m/z 308.1046
FI at m/z 378.0953
87
100
61
28
30
107.0497
185.0369
202.0629
308.1048
378.0950
C7H7O
C9H10O2Cl
C9H13O2NCl
C16H19O3NCl
C15H21O8NCl
-1.77
-2.34
0
-0.64
0.73
C12
G
25C-NBOMe-M (O,O-bis-demethyl-) glucuronide isomer 3 5.6
MS1 PM at m/z 484.1375 (M+H) 8 484.1369 C22H27O9NCl 1.26
MS2 FI at m/z 107.0495
FI at m/z 185.0365
FI at m/z 202.0628
FI at m/z 308.1047
FI at m/z 378.0952
55
100
30
29
9
107.0497
185.0369
202.0629
308.1048
378.0950
C7H7O
C9H10O2Cl
C9H13O2NCl
C16H19O3NCl
C15H21O8NCl
-1.77
-2.34
-0.66
-0.32
0.47
C16
G
25C-NBOMe-M (O-demethyl-) glucuronide isomer 1 5.5
MS1 PM at m/z 498.1526 (M+H) 15 498.1525 C23H29O9NCl 0.12
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 185.0365
FI at m/z 322.1205
52
100
1
13
91.0548
121.0653
185.0369
322.1204
C7H7
C8H9O
C9H10O2Cl
C17H21O3NCl
0
-1.98
-2.34
0.16
C17
G
25C-NBOMe-M (O-demethyl-) glucuronide isomer 2 6.4
MS1 PM at m/z 498.1524 (M+H) 8 498.1525 C23H29O9NCl -0.28
MS2 FI at m/z 91.0548
FI at m/z 121.0650
FI at m/z 185.0365
FI at m/z 322.1205
45
100
1
25
91.0548
121.0653
185.0369
322.1204
C7H7
C8H9O
C9H10O2Cl
C17H21O3NCl
0
-2.81
2.34
0.16
C18
G
25C-NBOMe-M (O-demethyl-) glucuronide isomer 3 7.0
MS1 PM at m/z 498.1525 (M+H) 14 498.1525 C23H29O9NCl 0
MS2 FI at m/z 107.0496
FI at m/z 199.0522
FI at m/z 216.0788
FI at m/z 322.1206
100
46
14
26
107.0497
199.0526
216.0786
322.1204
C7H7O
C10H12O2Cl
C10H15O2NCl
C17H21O3NCl
-0.84
-1.92
1.00
0.47
17
C19
G
25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) glucuronide isomer 1 3.9
MS1 PM at m/z 500.1320 (M+H) 6 500.1318 C22H27O10NCl 0.39
MS2 FI at m/z 107.0495
FI at m/z 137.0598
FI at m/z 324.0998
36
100
15
107.0497
137.0603
324.0997
C7H7O
C8H9O2
C16H19O4NCl
-1.77
-3.32
0.27
C20
G
25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) glucuronide isomer 2 4.5
MS1 PM at m/z 500.1318 (M+H) 12 500.1318 C22H27O10NCl 0
MS2 FI at m/z 123.0442
FI at m/z 185.0365
FI at m/z 202.0628
FI at m/z 299.0762
FI at m/z 324.0997
89
100
32
5
12
123.0446
185.0369
202.0629
299.0767
324.0997
C7H7O2
C9H10O2Cl
C9H13O2NCl
C13H15O8
C16H19O4NCl
-3.29
-2.34
-0.66
-1.66
0
C21
G
25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) glucuronide isomer 3 5.1
MS1 PM at m/z 500.1321 (M+H) 7 500.1318 C22H27O10NCl 0.59
MS2 FI at m/z 107.0495
FI at m/z 201.0313
FI at m/z 218.0578
FI at m/z 324.0997
FI at m/z 394.0906
52
100
36
31
4
107.0497
201.0318
218.0578
324.0997
394.0899
C7H7O
C9H10O3Cl
C9H13O3NCl
C16H19O4NCl
C15H21O9NCl
-1.77
-2.73
0
0
1.68
C22
G
25C-NBOMe-M (O,O-bis-demethyl-hydroxy-) glucuronide isomer 4 5.3
MS1 PM at m/z 500.1315 (M+H) 7 500.1318 C22H27O10NCl -0.61
MS2 FI at m/z 123.0443
FI at m/z 185.0365
FI at m/z 202.0628
FI at m/z 324.0996
FI at m/z 378.0945
100
25
11
9
1
123.0446
185.0369
202.0629
324.0997
378.0950
C7H7O2
C9H10O2Cl
C9H13O2NCl
C16H19O4NCl
C15H21O8NCl
-2.48
-2.34
-0.66
-0.35
-1.38
C27
G
25C-NBOMe-M (O-demethyl-hydroxy-) glucuronide isomer 1 5.5
MS1 PM at m/z 514.1483 (M+H) 6 514.1475 C23H29O10NCl 1.65
MS2 FI at m/z 107.0495
FI at m/z 137.0597
FI at m/z 185.0365
FI at m/z 313.0918
FI at m/z 338.1152
33
100
1
4
17
107.0497
137.0603
185.0369
313.0923
338.1154
C7H7O
C8H9O2
C9H10O2Cl
C14H17O8
C17H21O4NCl
-1.77
-4.05
-2.34
-1.74
-0.48
C28/29
G
25C-NBOMe-M (O-demethyl-hydroxy-) glucuronide isomer 2 6.5
MS1 PM at m/z 514.1479 (M+H) 8 514.1475 C23H29O10NCl 0.87
MS2 FI at m/z 123.0443
FI at m/z 199.0521
FI at m/z 216.0787
FI at m/z 338.1152
100
26
11
10
123.0446
199.0526
216.0786
338.1154
C7H7O2
C10H12O2Cl
C10H15O2NCl
C17H21O4NCl
-2.48
-2.43
0.54
-0.48
C31/32
G
25C-NBOMe-M (hydroxy-) glucuronide isomer 1 5.2
MS1 PM at m/z 528.1640 (M+H) 7 528.1631 C24H31O10NCl 1.70
MS2 FI at m/z 91.0548
FI at m/z 121.0651
FI at m/z 352.1313
46
100
18
91.0548
121.0653
352.1310
C7H7
C8H9O
C18H23O4NCl
0
-1.98
0.81
C33
G
25C-NBOMe-M (hydroxy-) glucuronide isomer 2 6.3
MS1 PM at m/z 528.1638 (M+H) 7 528.1631 C24H31O10NCl 1.32
MS2 FI at m/z 109.0652
FI at m/z 137.0598
FI at m/z 313.0921
FI at m/z 352.1324
73
100
17
3
109.0653
137.0603
313.0923
352.1310
C7H9O
C8H9O2
C14H17O8
C18H23O4NCl
-1.28
-3.32
-0.78
3.94
39
40
